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Synthetic cannabinoids have become a ubiquitous challenge in forensic toxicology and 
seized drug analysis. Acute toxic effects associated with these drugs include tachycardia, 
seizures, depression, possible suicidal tendencies, and the onset of psychotic episodes.  Synthetic 
cannabinoids were initially synthesized for research purposes in understanding the receptor-
ligand interactions at the CB1 and CB2 cannabinoid receptors. They are similar to Δ
9
-
tetrahydrocannabinol (THC) and also act as agonists at the cannabinoid receptors.  Originally it 
was hoped that this class of drug would be useful for pain relief, but instead this class of 
compounds has become widely abused, typically via smoking or heated vapor inhalation. The 
mode of ingestion is important in this context as heating creates many new potentially toxic 
agents, some of which may interact with the cannabinoid receptors as well.  
 The objectives of this research are to determine pyrolytic products produced from the 
smoking process of selected representative synthetic cannabinoids and evaluate their presence in 
true case samples to establish the necessity for inclusion in toxicological assessment.  This is a 
timely project given that current literature reports describe the detection of thermal degradation 
products of two synthetic cannabinoids in traditional toxicological matrices; blood and urine. 
Fundamental understanding of the toxic effects of thermal degradation products could assist 
forensic toxicologists in assessing intoxication and in development of new assays.  This 
knowledge could also be of use to the field of medicolegal death investigation and finally in the 
broader context of public health and safety. 
Proof of thermal degradation product production and ingestion are crucial to set a 
precedent for further studies of possible toxicity.  The current research utilizes an optimized 
pyrolysis methodology, where a predictive model for thermal degradation was established. An 
extraction and LC/MS/MS method was validated according to the guidelines set forth by the 
Standard Practices for Method Validation in Forensic Toxicology, and the project aids in 
achieving research goals on the set out by SWGTOX in August 2014; such as goal 3.1, 
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Chapter 1: Introduction 
1.1 Purpose 
1.1.1 Statement of the Problem 
In the past few years, notable progress has been made in identifying the metabolites of 
synthetic cannabinoids but there are two areas that remain relatively unexplored:  1) the toxicity 
and mechanisms of toxicity of these drugs and their metabolites; and identification of common 
pyrolytic products and their toxicity
1-10
.  The latter is critical given that the most common mode 
of ingestion of the synthetic cannabinoids is smoking or heated vapor generation.  Of particular 
concern to forensic toxicology, medicolegal death investigation, and public health and safety are 
the acute toxicities of these compounds.  The goal of this research is to provide foundational 
knowledge to these communities and to provide a framework for developing new diagnostic and 
analytical tools for use in the context.     
Synthetic cannabinoid products act on the same receptors as Δ
9
-tetrahydrocannabinol, the 
active ingredient within cannabis; however, they produce acute toxic responses that are not 
observed with the use of THC
11-16
.  The side effects are considered the “cannabinoid tetrad”, 
which includes (1) hypothermia, (2) analgesia, (3) catalepsy and (4) suppression of locomotor 
activity
17-23
.  Toxic effects outside of the tetrad also are observed in the renal, cardiovascular, 
respiratory and nervous systems. The increased use of these products and the accompanying 
dangers to users led the Drug Enforcement Agency to begin temporarily scheduling compounds 
such as JWH-018, JWH-073, JWH-200, CP-47,497 and CP-47,497-C8 homologue as Schedule I 
compounds under the Controlled Substances Act. Since then, additional compounds have been 
added in over the years, and to date, there are 33 Schedule 1 synthetic cannabinoids
15, 20-21, 24
.   
2 
 
Synthetic cannabinoids appeared in the mid-2000s primarily in Europe and soon 
thereafter in the United States
11, 15, 25-27
.  In 2009, a number of countries in Europe and the United 
States analyzed seized so-called “Spice” products, and numerous synthetic cannabinoid products 
such as JWH-073, CP 47,497 and HU-210 among others were detected in these products
11
.  In 
subsequent years, a large influx of synthetic cannabinoid products were introduced and became 
widely available which in turn led to an increased reporting by poison control centers and 
hospitals of synthetic cannabinoid ingestion
26, 28
.  In 2010, there were 2,906 suspected cases 
reported and 6,968 in 2011.  The number decreased in 2013 (2,668) and increased again in 2014 
(3,677)
29
.  Driving while intoxicated, overdose, and death cases that are unknowingly related to 
synthetic cannabinoid ingestion may not be accurately reflected in these statistics. 
The synthesis of THC analogs dates back to the 1960s when this family of drugs was first 
explored for use as pain relieving agents. Unanticipated acute toxic effects resulted in an end to 
this work and research attention turned to employing these compounds as research tools for 
understanding the structure of cannabinoid receptors and their receptor-ligand binding
11, 13, 15, 30
.  
In the 1970’s, Pfizer developed synthetic cannabinoids commonly termed cyclohexylphenols 
(CP), which are considered “non-classical” due to their lack of the benzopyran core of classical 
cannabinoids
11, 13
.  In the 1990’s, John W. Huffman began synthesizing the aminolkylindole 
synthetic cannabinoids (AAI), which contain napthyl and indole groups.  This family of 
compounds is identified by the JWH moniker
11, 13, 26, 31-32
. 
THC is an agonist for both the CB1 and CB2 cannabinoid receptors with roughly 
equivalent binding affinities for each.  THC has a CB1 binding affinity of 41nM, while early 
generation compounds JWH-018 and JWH-073 are 9nM and 8.9nM, respectively
33
.  CB1 
receptors are located in the central nervous system, which produce the psychological effects 
3 
 
observed in cannabis users
11-12, 14
. Synthetic cannabinoids are structurally different than THC but 
still elicit similar psychoactive responses to THC
11-14, 16, 22, 34
.  They also bind to the cannabinoid 
receptors, and the binding affinity of common synthetic cannabinoids is higher than that of THC.  
The increased potency has been reported to cause increased dependence over time and possible 
chronic health risks
35
.  The primary route of ingestion for these compounds is the inhalation of 
heated vapors.  This immediate bioavailability through absorption in the lungs coupled with the 




Recent work in forensic toxicology in the context of synthetic cannabinoids has focused 
on analytical assays.  Methods have been published for detecting synthetic cannabinoids along 
with their respective metabolites in toxicological matrices using hyphenated chromatographic/ 
mass spectrometry instrumentation and immunoassays
15, 22, 29, 31, 37-44
.  What is lacking from the 
current literature are reports and data describing these toxicants associated with the synthetic 
cannabinoids and associated pyrolytic products, their mechanisms of action, and how this 
information could be used to inform the interpretation of forensic toxicology data.  In a 2012 
publication, Wiebelhaus and Poklis et al. concluded that, “The increased potency of JWH-018 
compared to THC, the variable amount of drug added to various herbal products, and unknown 
toxicity, undoubtedly contribute to public health risks of synthetic cannabinoids”
45
.   
Additionally, in a 2011 article published in Clinical Biochemistry, Penn and Langman et al. 
stated, “The compounds were also extracted by boiling rather than vaporization into smoke, 
which raises the question whether smoking would generate pyrolysis products different from the 
parent drug”
46
.  Numerous pyrolytic products produced from the pyrolysis of the synthetic 





To the best of our knowledge, there has yet to be an extensive investigation into the 
ingestion and toxicity of the pyrolytic products produced when smoking synthetic cannabinoids.  
In a 2014 paper, Daw and Grabenauer et al. stated, “Synthetic cannabinoids degrade to other 
products when smoked. These pyrolysis products can be components that have an altered affinity 
to the CB1 and CB2 receptor or entities of unknown pharmacology and toxicology”
47
.  There 
have been a few studies into the cell toxicity of synthetic cannabinoid parent compounds, and 
these can be used as a basis for advancing and expanding work into pyrolytic compounds as they 
are demonstrated to be ingested.  Understanding the toxicity of the pyrolytic compounds could 
aid in filling the gap of toxicological knowledge regarding acute and chronic toxicity of synthetic 
cannabinoids and the associated issues related to forensic toxicology, medicolegal death 
investigation, and public health. 
1.1.2 Review of Research Literature 
One of the earliest studies that detected the presence of synthetic cannabinoids in an 
herbal incense product was in 2009, where the authors smoked a cigarette containing one of 
seven products they had collected
25
. Observations of the subjects were documented and several 
blood and urine samples were collected over time. The main synthetic cannabinoid detected in 
blood was the CP-47,497-C8 homologue. Subsequent analyses of the collected products, led to 
the discovery that JWH-018 was present in a number of the products. Pharm-THC, a licensed 
German company which produces and distributes Dronabinol®, went on record shortly after the 
report as saying they too had isolated JWH-018 from various seized Spice products
11, 28
. 
After these initial findings were publicized, a surge in research focusing on the analysis 
and detection of synthetic cannabinoids followed. In 2010, Teske et al detected JWH-018 in 
serum of two human subjects, but noted that after three hours, it was nearly undetectable by 
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liquid chromatography tandem-mass spectrometry (LC-MS/MS)
48
. Around the same time, two 
studies in Germany were conducted over a two year span to monitor the components found in 
herbal products.  More than 140 samples were analyzed from June 2008 to September 2009 
using GC-MS. Of the samples analyzed, 41 were found to contain no known synthetic 
cannabinoids, 28 were found to contain JWH-018, and 35 were found to contain JWH-073
49-50
.  
Sobolevsky et al. were one of the first to report the detection of urinary metabolites of JWH-018 
using gas chromatography tandem-mass spectrometry (GC-MS/MS) and LC-MS/MS
1
.   Urine 
samples were collected and analyzed by police from three individuals who confessed to using an 
herbal incense product within 12 hours of being arrested. GC-MS/MS tentatively identified two 
metabolites, while LC-MS/MS revealed another 11 tentative metabolites. The authors noted that 
no detectable amount of parent drug was present in the urine samples. 
The major metabolites of JWH-018 were determined in 2010 by in vitro phase I 
metabolism followed by Moller et al. reporting the findings from a study which screened 
approximately 7500 urine samples for JWH-018 and/or its metabolites for the purpose of human 
doping controls in 2011
2, 51
. Subsequently, the World Anti-Doping Agency specifically added 
products containing the synthetic cannabinoid JWH-018, JWH-073, and HU-210 to their 2012 
list of prohibited substances for athletes
52
. 
In 2011, the group from Germany fully validated a LC-MS/MS method for the analysis 
of multiple synthetic cannabinoids, including JWH-018 and JWH-073.  It was applied to 
approximately 100 serum samples provided from hospitals, police authorities, and rehabilitation 
centers, and the findings showed that after being banned by German legislation in 2009, JWH-
018 and JWH-073 were still found among products being sold. Of the 57 samples which tested 
positive for at least one synthetic cannabinoid, nine of them were positive for JWH-018, and six 
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were positive for JWH-073
53
. The validation of cannabinoid detection methods continues still, as 
in 2016 an LC/MS/MS method was reported that encompassed 32 synthetic cannabinoids
54
. Not 
long after, supplementary methods from both blood and urine specimens were published
55-58
. 
Papers using GC-MS and LC-MS/MS were published by Grigoryev et al. which reported 
the detection of metabolites corresponding to JWH-250 as well as JWH-018 and JWH-073 in 
human serum, human urine, and rat urine
4-5
.  The human serum and urine samples were collected 
from arrested individuals that confessed to using herbal incense products and analyzed within 24 
hours of arrest. A number of structures were tentatively identified as metabolites of the three 
synthetic cannabinoids, but no parent drug was present in detectable amounts, highlighting the 
need for assays which are capable of detecting the metabolites of these drugs
4-5
. Later in 2011, 
the first LC-MS/MS studies using authentic standards to quantify the metabolites of JWH-018 
and JWH-073 in human urine were published
59-60
. The more recent reports on newer generation 
cannabinoids shifted toward the use of hepatocytes for metabolic profiling, and the compounds 
analyzed included ADB-PINACA, 5F-ADB-PINACA, MAB-CHMINACA, MDMB-
FUBINACA, and ADB-FUBINACA
61-63
. An interesting report from 2016 allowed rats to inhale 
synthetic cannabinoids vapor and found that changes in dopamine and serotonin in brain 
microdialysates was observed, which could lead to neurotoxicity
64
. 
The next step in research was to understand the binding affinity and activity of the 
synthetic cannabinoids. Brents et al. hypothesized that the seemingly unexplained side effects of 
synthetic cannabinoids were due in part to the metabolites of JWH-018 not being deactivated. 
Upon examination of the six recognized JWH-018 metabolites, the authors found that one of the 
metabolites had the same binding affinity as JWH-018, which is almost 10-fold higher than 
THC, while four others had binding affinities nearly equivalent to that of THC
3
. A second paper 
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studied the binding of CP47,497-C8 and JWH-073. The authors found that both compounds had 
comparable affinity and activity at CB1 as the previous mentioned study found with JWH-018
14
.  
Later in 2013, a study compared the relative activities of a few synthetic cannabinoids and found 
that they declined in the order of JWH-122 > JWH-018 > JWH-210 > JWH-073 > THC
43
. Even 
more important for the current work is the 2017 finding of the UR-144 degradant maintaining a 
4-fold higher binding affinity at CB1 that even that of its parent compound
65
. This was supported 




Poklis et al. reported the first detection and disposition of JWH-018 and JWH-073 in 
mice after inhalation of a common herbal incense product, “Magic Gold,” in 2011. Five mice 
were sacrificed after 20 minutes and another five after 20 hours with both blood and brain 
samples being collected for subsequent analysis.  Using an LC-MS/MS assay, it was determined 
that blood concentrations were lower than in a similar experiment using THC, while an 
equivalent concentration was found in the brain
45
. Another LC-MS/MS study, investigated the 
detection and disposition of JWH-018 in mice after inhalation of a different herbal incense 
product, “Buzz.” This study determined the concentration of JWH-018 in the blood, brain, and 
liver of six mice sacrificed 20 minutes after exposure
67
. A third study, which sought to describe 
the behavioral effects observed after inhalation of the herbal incense product, “Buzz”, in mice, 
found that the effects from “Buzz” were similar to marijuana in terms of magnitude and time 
course; however, equal doses of both substances yielded considerably lower brain levels of 
JWH-018 than THC. The authors concluded that the increased potency of JWH-018 compared to 






A few studies have been completed in vitro to determine metabolic products of JWH-018, 
JWH-073, CP47, 497 and a newer generation compound, XLR-11. Typically, liver microsomes 
are used as the main cell line in the studies
9, 68-69
.  The most directly applicable to the research 
proposed here identified 13 phase 1 metabolites from JWH-018
68
.  Another study indicated that 
some phase 1 metabolites could be conjugated
70
.  This research however aims to move into the 
realm of pyrolysis.  Several drugs have been evaluated via pyrolysis including several in our 
laboratory
7, 42, 71-87
.  In the 1970s and 80s, the focus was on PCP, heroin and cocaine and later 
moved into methamphetamine and fentanyl
75, 86
. Recently a few reports were found on the 
synthetic cannabinoid UR-144 and a designer stimulant, mephedrone.  A recent publication 
reviews various classes of drugs of abuse and their pyrolytic products that have been identified 
throughout the years
10
. However, only four studies have been found dealing with the metabolism 
of a pyrolytic product.  The first three utilized the compound, UR-144, and the results of the 
study demonstrated that the pyrolytic products have independent metabolic pathways and thus 
can have additional toxicological properties.  The pyrolysis products and their metabolites are 
indicated by GC-MS, LC-MS/MS, NMR, and LC-QTOF-MS
7, 42, 72
.  Another study examined 
XLR-11 and its thermal degradation product, where the results show that the metabolites of the 
thermal degradation product were more prevalent than that of the parent compound
88
. These 
findings support the hypothesis underlying this proposed work that the pyrolytic products play a 
significant role in the context of intoxication, acute and chronic toxic effects, and potentially 
lethal toxic responses. 
Three papers in 2014 were published evaluating the toxicity of synthetic cannabinoids.  
The first investigated CP-47,497-C8, and the authors used buccal and liver cells to determine the 
concentration in which toxicity is observed
89
.  The paper indicated that the drug caused 
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interference with protein synthesis leading to membrane damage as well as DNA damage at 
concentrations of ≥7.5µM and ≥10µM, respectively
89
.  The second paper reviewed the toxicity of 
K2 products emphasizing that synthetic cannabinoids have higher potency and efficacy 
compared to THC, the synthetic cannabinoids have synergistic effects and that the metabolites 
maintain high affinity and activity at the CB1 and CB2 receptors
90
.  The final paper evaluated the 
toxicity in brain cells.  The authors first found that cell death was observed in a concentration 
dependent manner and that the cell death was triggered by the caspase-3 cascade.  By the use of 
CB1 and CB2 inhibitors, they also determined that the apoptotic pathway was controlled by the 
binding and activity at the CB1 receptor.  Overall, the peak toxicity began at 2 hours after dosage 




Only recently has research been able to dive into the pharmacology of synthetic 
cannabinoids due to the rapid generations of new compounds. In 2016, an investigation focused 
on the tert-leucinate compounds such as 5F-AMB, and the authors utilized in vivo studies to 
demonstrate higher potency than that of earlier generation compounds. Additionally, they found 
that hypothermia was reversed by a CB1 antagonist, but not with CB2
92
. In 2017, a review was 
conducted on the neurological effects of synthetic cannabinoids, and supported the notion that 
such drugs produce dependence
93
. 
1.1.3 Goals and Research Design 
 The aim of this project was to examine the process of thermal degradation via the 
smoking process to understand the scope at which the products may affect analyses. The issues 
of synthetic cannabinoid toxicity acting as the major influence on the research and fully 
understanding the thermal degradation process are crucial due to the main mode of ingestion, 
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smoking. There are current gaps in our understanding of cannabinoid effects including the 
mechanism of toxicity, and hypotheses span from unknown pharmacological activity to the 
observation of symptom overlap with serotonin syndrome. This research was conducted to 
determine the products, evaluate their presence in toxicological specimen and assess their 
possible connection to the additional toxicity of cannabinoid use observed. 
 The research design had three major phases; 1) Develop a pyrolysis apparatus and 
methodology 2) Determine the production of various thermal degradation products 3) Evaluate 
the presence of degradants in toxicological specimen. An apparatus with the capability to 
produce and collect the pyrolytic products across the volatility range within the means of the 
laboratory was the first step, and is outlined in Appendix B. After the apparatus was optimized, 
the second phase was to pyrolyze various synthetic cannabinoids and identify the thermal 
degradation products. This phase of the project is described in chapter 2, and indicated a few 
common breakdown pathways to be used as a predictive model. The final phase was to evaluate 
the degradants presence in a toxicological specimen in order to establish that such products are 
not just produced, but also ingested. Chapter 4 outlines this investigation, and the detection of 
pyrolytics in blood samples is a strong indicator that such products cannot be dismissed in 
synthetic cannabinoid assessments. 
1.2 Instrumentation 
1.2.1 Gas Chromatography – Mass Spectrometry (GC/MS) 
 Gas chromatography – mass spectrometry has been a staple in the field of forensic 
science for years. A GC/MS instrument is utilized as a confirmatory analysis by GC separation 
of sample analytes and MS interpretation for analyte identification. The components of a GC/MS 
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are displayed in Figure 1.1, including a carrier gas, sample injector, column contained in an 
oven, ionization source, mass analyzer, an electron multiplier and a data analysis system.  
 
 
Figure 1.1 – Schematic of a gas chromatograph – mass spectrometer 
 
The carrier gas and sample are injected into the column, which is held within a oven with 
controlled heat. As the heat is applied, the analytes within the sample are volatilized based on 
their individual properties, and separation is achieved as the analytes are carried through the 
column based on the partitioning of interaction between the mobile and stationary phases. The 
stationary phase is commonly a polysiloxane derivative that coats the inner walls of the silica 
glass capillary column, and the thickness can range from 0.5 to 5 µm. The oven that houses the 
capillary column is temperature controlled, which allows for temperature programming to 
facilitate separation. At lower temperatures, highly volatile analytes continue to flow, and as the 
temperature is ramped, the lower volatile analytes will begin to flow with the carrier gas.  
As analytes elute off of the GC column, they are directed into the mass spectrometer. 
Ionization of the analytes occurs upon introduction, and this is commonly achieved by electron 
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impact ionization (EI). In EI, the gaseous analytes are ionized via electron bombardment, 
typically at 70 eV, and the high-energy electrons cause the analyte to lose electrons and fragment 
due to the relaxation of the analyte from excited vibrational and rotational states. At this stage, 
there are charged fragments of various m/z, which are focused into the mass analyzer. 
There are different types of mass analyzers, but the most common and type used in the 
studies of chapters 2 & 3 is a quadrupole. A quadrupole is comprised of four cylindrical rods 
arranged in parallel fashion with dc and ac (RF) voltages applied across each. The ions travel 
through the space between the four rods, and the voltages on the rods are simultaneously 
increased and alternated. This produces an oscillating trajectory onto the ions, which allows for 
separation of the ions based on their m/z ratio. Upon exiting the quadrupole, the ions enter a 
detector, typically an electron multiplier, which amplifies and converts the ions into an electronic 
signal. The entirety of the mass spectrometer components is held under vacuum to ensure a free 
path of the ions throughout. The GC/MS analysis provides a chromatogram of retention time vs 
signal intensity, and a mass spectrum of m/z versus abundance. 
1.2.2 Liquid Chromatography – Tandem Mass Spectrometry (LC/MS/MS) 
 Liquid chromatography has become the standard technology in the field of forensic 
toxicology. LC/MS/MS analysis is a powerful confirmatory methodology, and a generic 
schematic is shown below in Figure 1.2. The mobile phase is comprised of different solvents 
that vary from aqueous based to more organic. A gradient mixture of the two solvents is used to 
elute analytes that are more soluble in either the aqueous or organic based solvent. Commonly, 
the initial mixture if highly aqueous, and throughout the gradient, the organic portion is increased 





Figure 1.2 – Schematic of a liquid chromatograph 
 
 
As the solvent are pumped towards the column, the injection valve is important in 
controlling sample volume before injection onto the column.  Figure 1.3 outlines a common 
valve and the two settings used to control the flow of solvent/sample to waste or to the column. 
As shown by the different numbered circles, there are 6 different ports, and the inner connecting 
channels can rotate to connect different ports as seen in contrast between A and B. Initially, the 
channels are connected as in A. In this position, the mobile phase in channeled to the column 
alone with no sample. At this time, the sample is being flushed into the sample loop and 
eventually to waste. This is where the sample volume is controlled, as based on the sample flow, 
the desired sample volume will be pumped into the sample loop. Next, the channels switch to 
position B. Now, the mobile phase is pumped into the sample loop, which in turns forces the 
previously place desired sample volume from the sample loop to be introduced onto the column. 
The analytes within the sample are then separated based on their tendency to interact with the 






Figure 1.3 – Schematic of an LC injection valve. A: Flow setting to fill the sample loop with 
desired volume. B: Flow setting to flush sample volume out of the loop and onto column. 
 
 
 LC columns are manufactured in multiple ways to advantageously separate different 
types of analytes by placing different propertied chemical groups on the the silica packing. The 
most common type of column is a C18 column, which is a chain of 18 carbons producing a non-
polar stationary phase. Depending on the desired separation, columns with other groups such as 
phenyls can be can be utilized. In the studies within chapter 4, a common C18column was used 
for a reverse phase based separation. The column also vary in length and packing , which 
produces smaller pore sizes for mobile phase flow or a longer separation time if necessary. The 
specifics of the column used in the current study are outlined in chapter 4.  
After separation is successful by the column, the analytes are introduced into the mass 
spectrometer, in which this case was a triple quadrupole tandem mass analyzer. Tandem mass 
spectrometers are classified into two categories; tandem-in-space or tandem-in-time.  The 
instrument utilized in the current research is the most common, tandem-in-space instrument.  The 
basic components of a triple quadrupole mass spectrometer instrument, depicted in Figure 1.4, 




Figure 1.4 – Schematic of a triple quadrupole mass spectrometer 
The ion source in this instrument employs electrospray ionization, ESI, source, which is a 
soft atmospheric pressure ionization technique in which ions transfer from solution into the gas 
phase. This technique uses differential pumping from atmospheric pressure to high vacuum, 
which is desired to allow for free movement of the analytes through the quadrupoles. 
Solution at a flow rate of 1-20 µL min
-1
 enters into a stainless-steel capillary held at a 
high potential of 3-4 kV.  Upon exiting the capillary, the emerging liquid is under the influence 
of an electric field, causing charge separation.  At the voltage in which pressure overcomes 
surface tension, a Taylor cone is formed and charged liquid emerges as droplets flowing in the 
direction of the counter electrode. A heated transfer capillary or curtain gas drives solvent 
evaporation.  Solvent continuously evaporates and the electric field of the droplet increases as a 
result of the decreasing radius causing the droplets to undergo Coulomb fission repeatedly until 
ion formation.  There are two models used to describe the formation of ions from charged 
droplets; charged-residue model (CRM) and ion evaporation model (IEM).  The CRM describes 
the formation of ions through solvent evaporation and declustering.  Conversely, the IEM model, 
describes the formation of ions through desorption from the droplet surface.  
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Once formed, the ions flow through the orifice of the curtain plate into the first 
quadrupole, where the first stage of separation occurs.  A quadrupole separates masses in the 
fashion described previously in Section 1.3.1.  It is here, in the quadrupole, that precursor ions 
are selected. The precursor ions then enter the second quadrupole, which is used as the collision 
cell, where ions interact with collision gas to produce product ions.  This process, called collision 
induced dissociation, CID, occurs and the resulting product ions pass into the third and final 
quadrupole for the second stage of mass separation.  The ions are then detected and a tandem 
mass spectrum is produced.  The ions are lastly detected and produce a tandem mass spectrum. 
Multiple reaction monitoring, MRM, was utilized to scan for multiple sets of transition ions for 
each analyte of interest. In using this method, it can further confirm the identification of an 
analyte by the observance of each transition and in the proper ion ratio. 
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Chapter 2: Qualitative Analysis and Detection of the Pyrolytic 
Products of JWH-018 and 11 Additional Synthetic Cannabinoids in 
the Presence of Common Herbal Smoking Substrates 
 
 This section of the research project evaluated the thermal degradation of 12 synthetic 
cannabinoids. It is important to state that the majority of the identifications in the below 
manuscript are tentative identifications based on any combination of a NIST library search match 
with a score of ≥75, a mass spectrum analysis or based off of similarity to another reference 
standard, which is further described in this preface. There were a number of the pyrolytic 
products that were able to be confirmed with a reference standard, however as most of these 
products have yet to be identified, there was a lack of reference standards available. Table 2.1 
below indicates the method of identification for the 52 thermal degradation products observed, 
and more detailed explanation of this process follows. 
Table 2.1 – Overview of the identification method for the thermal degradation products observed 
in the chapter 2 manuscript. If not indicated as confirmed, it is a tentative identification. 
Pyrolytic Product Method of Identification 
3-Hydroxyindazole Based on Indazole NIST Hit 
N-(1,2-dimethylpropyl)-Cinnolinamine Mass Spectrum Analysis 
1-Methylcyclohexanylindazole Mass Spectrum Analysis 
1-methylcyclohexanyl-N-(valinamidyl)-Cinnolinamine Mass Spectrum Analysis 
1-Methylcyclohexanyl-3-Cinnolinamine Mass Spectrum Analysis 
1-Methylbenzylcinnoline Mass Spectrum Analysis 
1-Pentylindazole-3-carboxaldehyde Mass Spectrum Analysis 
penten-4-yl-AB-PINACA Based on AB-PINACA Standard 
1-(5-fluoropentyl)-Indole Mass Spectrum Analysis 
1-(5-fluoropentyl)-Indole-3-carboxaldehyde Mass Spectrum Analysis 
3-Benzoylindole Mass Spectrum Analysis 
1-(5-fluoropentyl)-3-Benzoylindole Mass Spectrum Analysis 
3-Oxindole Confirmed 
1-Naphthalenecarbonitrile Confirmed 
2H-1-Benzopyran-2-one Mass Spectrum Analysis 
Methoxynaphthalene or 2-methyl-Naphthol Based on Naphthol Standard 
Naphthol Confirmed 
1H-Indole-3-ethanol NIST Library Match 
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penten-4-yl-JWH-018 Based on JWH-018 Standard 
1-butyl-Indole Based on Indole Standard 
1-butyl-Quinoline Based on Quinoline Standard 
1-Butylindole-3-carboxaldehyde Mass Spectrum Analysis 
1-butyl-3-Acetylindole Mass Spectrum Analysis 
buten-3-yl-JWH-073 Based on JWH-073 Standard 
penten-4-yl-JWH-081 Based on JWH-081 Standard 
1-Pentylquinoline Based on Quinoline Standard 
N-penten-4-yl-JWH-210 Based on JWH-210 Standard 
3-(1-methylnaphthoyl)-Indole Mass Spectrum Analysis 
N-propyl-3-(1-methylnaphthoyl)-Indole Mass Spectrum Analysis 
UR-144 Degradant Confirmed 
1-(5-fluoropentyl)-Indole-3-carboxaldehyde Mass Spectrum Analysis 
XLR-11 Degradant Confirmed 
Naphthalene Confirmed 
Quinoline Confirmed 





4-Cinnolinamine NIST Library Match 
1-Pentylindole Mass Spectrum Analysis 
1H-Indazole-3-carboxaldehyde Confirmed 
1-Pentylisatin Based on Isatin Standard 
N-(2-methylpropyl)-4-Cinnolinamine Mass Spectrum Analysis 
1-Pentylindole-3-carboxaldehyde Mass Spectrum Analysis 
1-pentyl-3-Acetylindole Mass Spectrum Analysis 
(1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)-Methanone Mass Spectrum Analysis 
1-Methylindazole Confirmed 
1-Methylindazole-3-formamide Mass Spectrum Analysis 
N-methyl-3-Naphthoylindole Mass Spectrum Analysis 
N-phenyl-1-Naphthamide NIST Library Match 
3-Naphthoylindole NIST Library Match 
JWH-018 Confirmed 
 
 For the products in which there was no reference standard and no direct library match, a 
mass spectrum analysis was carried out based on any structural library hit, a plausible thermal 
breakdown from the parent compound and similarity to a reference standard. For example, a 
product such as 1-butyl-indole had no reference standard for comparison. Here the mass 
spectrum would be compared to that of the indole reference standard to establish a comparable 
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fragmentation pattern other than additional fragments above the mass of indole and a parent peak 
of an extra 57 Da. Herein it is proposed that the additional 57 Da is from a butyl chain bonded to 
the indole ring. This is supported by the fact that JWH-073 contains a butyl chain on the indole 
ring, which was the parent cannabinoid to produce this product. This remains a tentative 
identification, and is based on the structure of JWH-073 and observed MS of a reference 
standard, indole. This process was carried out on a number of the proposed pyrolytic products, 
but further confirmation is necessary. Another method for predicting the identification was to 
work off any library search hit. Here, if the library produced a high match probability for a 
compound such as indole, but the observed MS has a much higher mass molecular ion peak, it is 
clear that the product is not indole itself, though may contain an indole ring. In this case 
predictions were based on building possible structures from the parent cannabinoid and with the 
indole intact based on the library hit. This is by no means a confirmation, but a basis for the 
proposed pyrolytic product, in which further confirmation is necessary in supplemental research. 
This project has set the groundwork for identifying pyrolytic products, but is only the first step in 
this process. Next, it is needed to be reproduced, and reference standards synthesized to confirm 














Reproduced from the Journal of Analytical Toxicology. Qualitative Analysis and Detection of the 
Pyrolytic Products of JWH-018 and 11 Additional Synthetic Cannabinoids in the Presence of 
Common Herbal Smoking Substrates. . S. Raso and S. Bell, Journal of Analytical Toxicology 41, 
6, 551-558, 2017.  
Permission was obtained from the co-authors and the Journal of Analytical Toxicology 
according to the journal’s license’s, copyright and permissions policy. A copy of the permissions 
agreement is shown in Appendix A. 
Synthetic cannabinoids have become a ubiquitous challenge in forensic toxicology and 
seized drug analysis. Thermal degradation products have yet to be identified and evaluated for 
toxicity in comparison to parent and metabolic compounds.  An investigation into these pyrolytic 
products, as the major route of ingestion is inhalation, may produce additional insight to 
understand the toxicity of synthetic cannabinoids. The pyrolysis of JWH-018 and 11 additional 
synthetic cannabinoids and six herbal plant substrates were conducted using an in-house 
constructed smoking simulator. After pyrolysis of herbal material alone, the plant substrate was 
spiked with the drug compounds to 2-5% w/w concentrations. Samples were collected, filtered, 
evaporated under nitrogen gas, reconstituted in methanol, and analyzed via gas chromatograph-
mass spectrometer (GS/MS). Pyrolysis of the plant material alone produced 10 consistently 
observed compounds between the six plant species. The pyrolysis of the synthetic cannabinoids 
produced a total of 52 pyrolytic compounds, where 32 were unique to a particular parent 
compound and the remaining 20 were common products between multiple cannabinoids. The 
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thermal degradation followed three major pathways that are outlined to assist in producing a 
predictive model for new synthetic cannabinoids that may arise in case samples. The observed 
pyrolytic products are also viable options for analysis in post mortem samples and the evaluation 
of toxicity. 
2.1 Introduction 
In recent years, notable progress has been made in identifying the evolving generations of 
synthetic cannabinoids and their corresponding metabolites. However, two areas remain 
relatively unexplored:  1) the toxicity and mechanism of toxicity of the parent drugs and their 
metabolites; and 2) identification of common pyrolytic products and their toxicity
1-10
.  The latter 
is critical given that the most common mode of ingestion of synthetic cannabinoids is smoking or 
heated vapor inhalation.  The acute toxicity of this abuse is of particular concern to forensic 
toxicology, medicolegal death investigation, and public health and safety.  
Synthetic cannabinoid abuse appeared in the mid-2000s, primarily in Europe and soon 
thereafter in the United States
11-15
.  These compounds mimic Δ
9
-tetrahydrocannabinol (THC), the 
active ingredient of cannabis; however, they produce acute toxic responses that are not observed 
with the use of THC
11, 14, 16-19
.  The additional side effects, referred to as the “cannabinoid tetrad” 
include (1) hypothermia, (2) analgesia, (3) catalepsy and (4) suppression of locomotor activity
20-
26
.  Recent work in forensic toxicology in the context of synthetic cannabinoids has focused on 
analytical assays, and methods have been published for detecting synthetic cannabinoids along 
with their respective metabolites in toxicological matrices using hyphenated 
chromatographic/mass spectrometry instrumentation and immunoassays
14, 25, 27-37
.  Lacking from 
the current literature are reports and data describing the synthetic cannabinoid pyrolytic products, 
mechanisms of toxicity of these species, and how this information could be used in the 
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interpretation of forensic toxicology data.  At least two authors have expressed the need to 
address these research gaps
38-39
. To date, few pyrolytic products have been identified with only 
two being observed in toxicological matrices, UR-144 and XLR-11 degradants
28, 40
. Further 
identification of pyrolytic products may provide insight into the cause of additional acute 
toxicities. 
 The process of smoking is difficult to simulate given that the heated environment is 
thermally and chemically heterogeneous. Reaction zones of both oxidative and reductive 
chemistry may exist, altered by the process of inhalation. As a result, realistic and reproducible 
simulation of ingestion by smoking is difficult. Furthermore, there is no way to establish what 
compounds produced by smoking remain in inhaled air for delivery to the lungs and absorption 
into the bloodstream. In light of these considerations, exhaustive sampling and collection 
methods are a reasonable alternative as a starting point. A number of techniques have been used 
for conducting pyrolysis experiments, as summarized in a recent review, and include analytical 
pyroprobes, heating in sealed capillary tubes followed by extraction, and solvent 
trapping/impinge-like devices
10
. Each technique is geared toward collecting particular types of 
products. When utilizing a capillary tube or any apparatus to contain the sample while heating 
followed by extraction, the more volatile products are lost. Conversely, using an analytical 
pyroprobe, which connects to a GC inlet via a transfer line, may limit the sampling of the less 
volatile materials.  
This paper describes results to date of a comprehensive characterization of the pyrolytic 
products associated with selected synthetic cannabinoids and six herbal substrates commonly 
seen in street samples. The work was accomplished using a device built in-house and designed to 
collect as many products as possible, from the most volatile to least. The analytical method was 
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optimized using replicate and duplicate analyses starting with herbal mixtures without 
cannabinoids. These experiments established compounds that would be expected to arise from 
the substrate and to differentiate these from compounds arising from the synthetic cannabinoids. 
Using the optimized experimental procedures, each synthetic cannabinoids was characterized. 
The results were used to identify common pyrolytic pathways and to develop methods that will 
allow for prediction of pyrolytic products of new cannabinoids. 
2.2 Methods 
 The experimental procedures spanned optimizing the constructed apparatus, evaluation of 
the designed method protocol, pyrolysis of herbal matrices and pyrolysis of synthetic 
cannabinoids. The apparatus was checked for air flow consistency and temperature to ensure 
adequate heat was acquired to induce pyrolysis. Initially, the method protocol specifically 
regarding sample collection was evaluated to optimize the collection of all pertinent produced 
products. Following the method checks, the herbal matrices were pyrolyzed to determine 
background pyrolytics, and finally the synthetic cannabinoid compounds were pyrolyzed.  
2.2.1 Materials and Reagents 
 All portions of the apparatus involved directly in the pyrolysis are constructed of quartz 
or Teflon to endure high temperatures. Quartz glass tubing was obtained from Quartz Scientific, 
Incorporated (Fairport Harbor, OH) in the following sizes: Inner diameter (I) of 1mm, outer 
diameter (O) of 3mm and wall width (W) of 1mm; I=7mm, O=9mm and W=1mm; and I=10mm, 
O=12mm and W=1mm. Quartz wool was purchased from Acros Organics (New Jersey, USA). 
Heat was applied using a Benzomatic® propane torch from Worthington Cylinder Corporation 
(Columbus, OH). Pressure levels were controlled with a model VP2S CPS Pro-Set Vacuum 
Pump (Hialeah, FL) and a pressure gauge from Valworx Incorporated (Cornelius, NC). The 
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temperature was monitored using a HH506RA Multilogger Thermometer, a K-Type 
thermocouple and 0.20mm CH
+
  and 0.20mm Al
-
  wires from Omega Engineering, Incorporated 
(Stamford, CT). Sampling utilized 5mL LUER-SLIP plastic syringes and 17mm, 0.45μm syringe 
filters  from Thermo Fisher Scientific (Waltham, MA) with collection in Methanol from Fisher 
Scientific (Hampton, NH). Six herbal species including Nymphaea caerulea commonly called 
Blue Lotus, Nepeta cataria or Catnip, Turnera diffusa or Damiana, Zornia latolia or Maconha 
Brava, Althaea officinalis or Marshmallow Leaf and Combretum quadrangulare or Sakae Naa 
were purchased from Bouncing Bear Botanicals (Lawrence, KS). Synthetic cannabinoid 
standards of AB-CHMINACA, AB-FUBINACA, AB-PINACA, AM-694, AM-2201, JWH-018, 
JWH-073, JWH-081, JWH-210, MAM-2201, UR-144 and XLR-11 were purchased from 
Cayman Chemical Company (Ann Arbor, MI).  
2.2.2 Apparatus 
The in-house constructed apparatus utilized a T-junction of quartz tubing to contain the 
pyrolysis reaction, and positioned into a 250mL Erlenmeyer vacuum flask via rubber stopper so 
that the tip of the tube sits in the capture solvent. The flask is connected to vacuum for consistent 
air flow producing a light bubbling in the capture solvent. Using the pressure gauge, a setting of 
2 inHg was chosen, which equates to 6.77 kPa. A major issue with mimicking the smoking 
process is the inherent variability of the process, whether in a cigarette, “joint” or in any version 
of a bong. While it is difficult to evaluate how closely a given design mimics a smoking process, 
it is possible and essential to record at which temperature pyrolysis takes place. For temperature 
monitoring, thermocouple wires were placed in the reaction zone. The wires were kept apart with 
plastic coating and inserted through the shorter piece of the T-junction by a series of smaller 
quartz tubes held together with a Teflon plug to ensure to wires only came in contact, which 
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enables temperature recording, within the reaction zone. A photograph of the constructed 
apparatus, schematic information of the T-junction and Teflon plug, and heat signature data is 
included in Appendix B.  
2.2.3 Sample Preparation 
 The samples of herbal material needed to preparation, and were weighed out to constant 
masses and introduced to the apparatus. Each synthetic cannabinoid sample was prepared 
individually over a two to three-day period. The plant material mass was kept constant to ensure 
the pyrolysis atmosphere was consistent between trials, and the drug mass used was calculated 
thusly to produce a concentration level within the range of 2-5 % by weight in milligrams. The 
synthetic cannabinoid standard was dissolved in methanol and sprayed onto the herbal material. 
This was conducted with movement of plant material in effort to homogenize spread of the drug 
compound. The sample sat overnight to allow the methanol to completely evaporate, leaving the 
drug compound behind on the herbal matrix.  
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Figure 2.1 – A reproduced MS spectrum of predicted product, N-(1,2-dimethylpropyl)-4-
cinnolinamine, along with its predicted fragmentation pattern. 
 
2.2.4 Sample Collection 
 Control samples from the apparatus and unburnt materials were initially analyzed. The 
collection method utilizes methanol as the solvent, so unburnt quartz wool and each herbal 
species in duplicate were soaked in methanol and analyzed via GC/MS.  The quartz wool 
produced an equivalent spectrum to a methanol blank as expected. Any observed 
chromatographic peaks observed in both samples from the herbal material not seen in either the 
methanol or quartz blank were noted, and these background compounds were acknowledged as 
being present before herbal material and synthetic cannabinoid pyrolysis and thus not a pyrolytic 






















































Upon completion of a given burning experiment, three samples are collected from the 
apparatus. From the reaction zone, the quartz wool plugs and any leftover ashes are transferred to 
a 5mL LUER-SLIP plastic syringe fitted with a 0.45µm filter. The contents are filtered with 5mL 
of methanol and collected in a 10mL vial as the first sample. The second sample is also collected 
into a 10mL vial after rinsing the T-junction tube with 10mL of methanol.  The capture solvent 
from the 250mL vacuum flask, which is 50mL of methanol, is transferred to a 100mL beaker as 
the third sample. All samples were evaporated under nitrogen and reconstituted in methanol.  
The capture solvent was reconstituted to 10mL, transferred to a 10mL vial, re-evaporated and 
reconstituted to a final volume of 2mL. The rinse from the tube was reconstituted to a final 
volume of 2mL, and the quartz/ashes sample was reconstituted to 500µL.  
2.2.5 Instrumental Analysis 





 30m x 250µm x 0.5µm column coupled with a Clarus 
SQ8T mass spectrometer. Helium was used as the carrier gas with a flow of 12.1 mL/min. The 
injection volume was a splitless 2µL with the heater set at 275°C. The gas chromatography (GC) 
method had an initial temperature of 100°C, ramp of 20°C/min and was held at 320°C for 15min. 
The mass spectrometer (MS) was set with a 1.00min solvent delay, scan time of 0.2sec and a 
range of 40-500 m/z.  
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Figure 2.2 – Breakdown chart of JWH-018 to its proposed observed pyrolytic products; (*) 
unique products. 
 
2.2.6 Synthetic Cannabinoid Pyrolysis  
Prior to analyzing the synthetic cannabinoids, compounds that arose from pyrolysis of the 
herbal material alone were characterized. This process and results are described in Appendix B, 
and the results were consistent with previous plant pyrolysis studies demonstrating that the 
current methodology is suitable for the present application. 
An optimization of experimental conditions was performed to determine the number of 
replicates and the number of extractions and rinses necessary to maximize recovery of pyrolytic 
products from the synthetic cannabinoids. This was accomplished through a series of 5 replicate 
experiments using JWH-018 on Damiana with exhaustive sampling. This sampling schematic is 
outlined in Appendix B. Results of these experiments demonstrated that a single wash is 
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necessary for both quartz/ashes and tube samples. Additionally, consistent data was observed 
through the five trials, and it was determined that three trials was sufficient to acquire all 
variations of products. As a result, the remaining JWH-018 trials on the other five herbal 
matrices was carried out at an n=3 using only a single rinse for sample collection. Upon 
completion of JWH-018 analyses, no differentiation of results was observed between the six 
herbal matrices. The remaining 11 synthetic cannabinoid analyses were performed using the 
same parameters as JWH-018, but only on a single herbal matrix, Damiana. 
2.2.7 Data Analysis 
The data analysis stepwise limited the chromatographic peaks of interest to those 
consistently observed. Initially, chromatographic peaks were limited to those with a signal to 
noise ratio greater than 5, as calculated by TurboMass 6.1.0 software.  They were further 
narrowed down those consistently present in at least two of the three trials within a retention time 
window of +/- 0.05 min. The remaining peaks were noted as a possible pyrolytic product and 
evaluated for tentative identification. The identification process is difficult for such products due 
to the lack of standards available. Initially, a library search using the National Institute of 
Standards and Technology (NIST/NIH) database was carried out to obtain a starting point of a 
possible general structure. Mass spectrum analysis was conducted to insure the fragment 
breakdown was plausible for the predicted pyrolytic compound, and an example of this is shown 
in Figure 2.1. Additionally, the chromatography was evaluated via retention index (RI) where 
possible. This combined data analysis along with a logical mechanism of production via 
pyrolysis was used to predict compound identifications, but these were not confirmed with 




2.3.1 Synthetic Cannabinoid Pyrolysis 
 The pyrolysis trials of the synthetic cannabinoids yielded 52 pyrolytic products, and each 
was found to have presence in the smoke as detected in either the tube or solvent samples, with 
little to none detected left behind in the quartz/ashes sample. This indicates a potential for harm 
as they travel within the inhaled smoke or off to the local atmosphere and may affect an innocent 
bystander.  Of the proposed pyrolytic products, 32 were unique to a particular parent compound 
studied. The unique products might be exploitable as additional markers of synthetic cannabinoid 
use even when the parent compound is not detected. Assuming that these pyrolytic products 
reach the body and are absorbed, this may widen the scope of toxicological analysis by providing 
analytes outside of the typical parent and metabolic compounds. Further studies into the 
metabolism, pharmacokinetics and pharmacodynamics are necessary to understand the effects of 
these products after production via the smoking process. Table 2.2 lists the suggested products 
along with their respective parent synthetic cannabinoid, and Figure 2.2 outlines an example 
breakdown of parent to the predicted pyrolytic products. Two important pyrolytics to note were 
the degradants of UR-144 and XLR-11, as these are the two previously detected pyrolytics 
within toxicological samples, and their presence strengthens the utility of the current method as it 
is in agreement with expected pyrolytic compounds previously detected
28, 40
. Additionally, Daw 
et al reported a possible pyrolytic trend of a 2 hydrogen loss at the end of the N-alkyl chain 
where present
39
. This trend was observed here with synthetic cannabinoids AB-PINACA, and 
JWH-018, -073, -081 and -210. 
 Figure 2.2 further illustrates examples of three common breakdown tendencies across the 
pyrolysis of all 12 synthetic cannabinoids. The first is a break on either side of the central 
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carbonyl group commonly present in synthetic cannabinoids. This breakdown trend produces 
pyrolytics such as indole or naphthalene products. The second trend, predictable due to the weak 
C—N bond, is the loss of the substituent group bonded to the nitrogen of the indole or indazole 
ring structures. An example of this in Figure2.2 is the proposed product, 3-Naphthoylindole, or 
other such products such as Formylvaline amide from AB-PINACA and 3-Benzoylindole from 
AM-694. The last is the common pyrolytic process of a ring size increase. Majority of synthetic 
cannabinoids have either an indole or indazole ring structure, and with the pyrolytic ring size 
increase, they convert to a quinoline or cinnoline ring structure respectively. These breakdown or 
conversion trends can be used for a prediction model for the thermal degradation of the 
continually evolving generations of synthetic cannabinoids. 
Separate from the unique pyrolytic products for each cannabinoid, the remaining 20 
suggested products were shared between at least two of the parent synthetic cannabinoids 
studied, typically similar in structural class. These products are outlined in Table 2.3 and 
indicate which parent compounds produced each pyrolytic product. The detection of these 
products could not be used to indicate the use of any specific synthetic cannabinoid, but can be 
an indication for the use of synthetic cannabinoids in general or possibly limit the search to a 
structural class such as naphthoylindoles, indazoles or tetramethylcyclopropyls. Figure 2.3 
shows an example breakdown of the different parent synthetic cannabinoids that produced the 
pyrolytic, quinoline. It can be noted that each parent compound includes an indole group, and 
this type of trend could be exploited to limit a search to those with an indole moiety if quinoline 
was detected during analysis if additional information points toward synthetic cannabinoid use. 
A limitation here would be other drug compounds that may also share quinoline as a pyrolytic 
product, but is still useful as a starting point during investigation. 
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Table 2.3 – Proposed pyrolytic products with the parent synthetic cannabinoids they are 
commonly produced from; a) AB-CHMINACA b) AB-FUBINACA c) AB-PINACA d) AM-694 
e) AM-2201 f) JWH-018 g) JWH-073 h) JWH-081 i) JWH-210 j) MAM-2201 k) UR-144 and l) 
XLR-11 
2.4 Discussion 
 Due to the major route of ingestion of synthetic cannabinoids being inhalation through a 
smoking process, an understanding of the pyrolytic breakdown of these compounds is important 
for full analysis in toxicological samples. Pyrolysis has been studied in the past with different 
techniques; however they had the tendency to focus on either the most or least volatile products. 
There is lacking data on the majority of products’ volatility, but a few where there is, indicate the 
ability of the reported methodology to collect products across the volatility range. A few high 
Pyrolytic Product Parent Compounds 
Naphthalene f, g, h 
Quinoline e, f, g, h, i, j, k 
Formylvaline amide a, c 
Indole e, f, g, h, i, j 
Methylindole e, f 




1-Pentylindole f, l 
1H-Indazole-3-carboxaldehyde b, c 
1-Pentylisatin f, l 
N-(2-methylpropyl)-4-Cinnolinamine a, b, c 
1-Pentylindole-3-carboxaldehyde d, e, h, i, j, k, l 
1-pentyl-3-Acetylindole e, h, i, j, k, l 
(1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)-Methanone k, l 
1-Methylindazole a, b 
1-Methylindazole-3-formamide b, c 
N-methyl-3-Naphthoylindole f, g, i 
N-phenyl-1-Naphthamide g, i 
3-Naphthoylindole f, h, j 
JWH-018 e, h 
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volatile product examples are indole, quinoline and naphthalene whose vapor pressure levels are 




. On the other side of the spectrum, low volatile parent 
compounds such as JWH-018 and JWH-073 whose vapor pressure is on the order of ~10
-10
 
mmHg were also collected
44-45
. 
 The constructed apparatus demonstrated the ability to produce a “smoking-like 
environment”, which is important as synthetic cannabinoids are often smoked using an herbal 
matrix laced with the compound of interest. Six common herbal materials were pyrolyzed to 
determine background products to differentiate from those pyrolytics of synthetic cannabinoids, 
and ten consistent products, which were tentatively identified, were detected and consistent with 
previous pyrolysis studies on plant material demonstrating the methodology was fit for pyrolytic 
analyses. 
 
Figure 2.3 – Chart displaying each parent synthetic cannabinoid that produced quinoline. 
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 The pyrolysis trials of the synthetic cannabinoids produced fifty two pyrolytic products. 
Thirty two of these proposed products were unique to a particular parent cannabinoid compound, 
whereas the remaining twenty were shared by multiple parent compounds. The unique pyrolytic 
products are important, as they may serve as additional toxicological markers and indicate use of 
a specific synthetic cannabinoid without detection of the parent or metabolic compound. The 
shared pyrolytic products are not an indication of a specific cannabinoid, but are a useful 
suggestion of synthetic cannabinoid use. Another powerful tool for these thermal degradants is 
for the analysis of drug paraphernalia for the presence of synthetic cannabinoids. Both the unique 
and shared products provide beneficial information to the field, as of now, they are limited to 
those synthetic cannabinoids included in the current study. It cannot be said that other 
compounds or future generations will not produce equivalent pyrolytics. Further studies are 
necessary as well as synthesis of reference standards to confirm the products proposed. To reach 
a level of unambiguity of the identification of the proposed products, chromatographic analysis 
of reference standards as well as structural analysis via FTIR and NMR will be necessary.  
Upon analysis of the studied cannabinoids, three major thermal degradation trends were 
apparent including: 1) a break on either side of the central carbonyl; 2) loss of the 
indole/indazole N-bonded substituent group; and 3) a ring size increase from indole/indazole to 
quinoline/cinnoline respectively. These trends may be used as a predictive model for other 
synthetic cannabinoids not studied here, not yet seen in casework, or for future generations yet to 
be synthesized.  
The current study has set the stage for further investigation into the pyrolysis of synthetic 
cannabinoids as multiple products have been proposed, which could be utilized in various facets 
of forensics. Future steps are to quantify this process as to obtain an idea of the percent 
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breakdown of these compounds that can be expected as well as investigating their presence in 
biological matrices. If they do in fact reach the body, they may produce toxic effects. The World 
Health Organization (WHO) has not classified the proposed products, but other indole, 





 The reported methodology was demonstrated as a suitable means for pyrolysis studies, 
and the performed analyses lay the groundwork for beginning to understand the effect of 
pyrolysis on synthetic cannabinoids. Ten pyrolytic products were observed in the herbal 
substrate trials, and fifty two pyrolytics were detected from the pyrolysis of the synthetic 
cannabinoids. The understanding of how the synthetic cannabinoids thermally degrade, via three 
observed breakdown or conversion trends, provides a predictive model to be used on additional 
compounds. The proposed pyrolytics also may provide additional analytes to be analyzed in 
toxicological samples and for use in toxicity studies.  
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Smoking as a route of ingestion of drugs of abuse is still common amongst users, and this 
poses numerous health risks both to the users and bystanders. It is understood that drug 
compounds thermally degrade during the smoking process, but knowledge of the effects of such 
products is still lacking. This report employs a previously optimized in-house method to 
consolidate previously unconfirmed pyrolytic results as well as identify newly observed products 
of drugs including cocaine, heroin and phenethylamines. This methodology has already 
demonstrated its ability to evaluate the pyrolysis process with a number of synthetic cannabinoid 
compounds, and the current opioid crisis led to the movement back to the classical drugs. In the 
1980’s, a type of encephalopathy specifically seen in heroin smokers was coined heroin induced 
spongiform leukoencephalopathy or HSL. As this effect had a larger observance in smokers 
versus injectors, hypotheses of the produced thermal degradants having additional 
pharmacodynamic effects arose. After analysis, different previously detected as well as newly 
observed degradants were identified. Interestingly, some of the products are even metabolic 
products, and the impact the identified products may have span across drug investigations, 




A critical review of thermal degradation studies of drugs of abuse was published by our 
group in 2015
1
.  The impetus for this project was to consolidate findings to date related to drugs 
of abuse such as heroin and cocaine and to provide a foundation for work regarding novel 
psychoactive substances (NPSs), primarily synthetic cannabinoids.  The fact that these 
compounds are ingested primarily by smoking (and now “vaping”) coupled with the 
constellation of toxic effects observed has driven this interest.  As examples, XLR-11 and UR-
144 both contain a cyclopropyl group that opens with heating to form known degradation 
products referred to as degradants which are detectable in toxicological samples
2-5
. It is also 
observed that these degradants produce a metabolic profile separate from the parent 
compound
3
.This renewed interest in thermal degradation products has benefited from improved 
instrumental capability over what was available even fifteen years ago.  Accordingly, the goal of 
this project was to revisit earlier thermal degradation studies of drugs such as cocaine, heroin, 
and phenethylamines using optimized experimental conditions and designs coupled with 
improved instrumental detection methods.   
While greater attention is being paid to NPSs, these “older” drugs remain a forensic, legal, 
and public health challenge.  Heroin and related synthetic opioids have become the current 
greatest overdose threat. The National Institute of Health (NIH) testified to this issue in front of 
the senate, stating a current heroin use population of nearly 1 million
6-7
. Unlike synthetic 
cannabinoids, opioids are ingested by injection, snorting, and smoking, but issues related to 
smoking and thermal degradation products has long been a concern.  Beginning in the 1980’s, it 
was observed that heroin users that smoked the drug had higher mortality rates due to a type of 
encephalopathy called heroin induced spongiform leukoencephalopathy, HSL, which was not 
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seen in users who instead utilized injection
8-26
. This led to initial investigations into the pyrolytic 
process of smoking illicit drugs and tentative identification of any thermal degradation products. 
The current investigation employed a proven in-house method to revisit the pyrolysis of 
commonly smoked illicit drugs and demonstrate the production of both previously observed 
thermal degradation products as well as several newly identified products
27
.  The findings are 
interpreted in the context of current understanding related to the potential toxicity of the thermal 
degradation products and effect on metabolite presence interpretation.   
3.2 Methods 
3.2.1 Materials and Reagents 
 An apparatus to carry out controlled pyrolysis experiments was constructed in-house and 
specifications previously reported
27
. Sample collection utilized 5mL LUER-SLIP plastic syringes 
and 17mm, 0.45μm syringe filters from Thermo Fisher Scientific (Waltham, MA) with methanol 
as the solvent from Fisher Scientific (Hampton, NH). Standard solids of methamphetamine, 
cocaine, heroin, and fentanyl were obtained from Sigma-Aldrich (St. Louis, MO). 
3.2.2 Pyrolysis Trials 
Solid reference standards were analyzed individually by being placed directly into the 
reaction zone of the previously described apparatus. No additional sample preparation was 
required. The reaction zone is enclosed with quartz wool to contain the pyrolysis of the drug 
while constant air flow was controlled with the vacuum pump. The pyrolysis study of each 
compound was conducted in replicates of 5 with each experiment utilizing 20 mg of reference 
standard. Two additional experiments were carried out with a mixture of heroin and fentanyl 
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given the current increase in fentanyl/heroin street samples. These mixtures were prepared to be 
50 % w/w of each compound. 
3.2.3 Sample Collection 
After heating, three samples were collected from different locations in the apparatus as 
previously described
27
. Samples were evaporated under nitrogen and reconstituted in fresh 
methanol.  The capture solvent was initially reconstituted to 10mL, transferred to a 10mL vial, 
re-evaporated and reconstituted to a final volume of 2mL. The rinse from the tube was also 
reconstituted to a final volume of 2mL, while the quartz/ashes sample was reconstituted to 
500µL. Each solid sample resulted in solutions, one from each location and for each drug, 5 
individual samples were subjected to thermal degradation. 
3.2.4 Instrumental Analysis 





 30m x 250µm x 0.5µm column coupled with a Clarus 
SQ8T mass spectrometer. Helium was used as the carrier gas with a flow of 12.1mL/min. The 
injection volume was a splitless 2µL with the heater set at 275°C. The gas chromatography (GC) 
method had an initial temperature of 100°C, ramp of 20°C/min and was held at 320°C for 2min 
for a total run time of 13min. The mass spectrometer was set with a 1.00min solvent delay, scan 
time of 0.2s and a range of 40-500 m/z. 
3.2.5 Data Analysis 
The first step in the analysis scheme was selection of which chromatographic peaks to 
consider.  Only those peaks that were consistently present in at least three of the five trials were 
selected for further evaluation.  A library search using the National Institute of Standards and 
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Technology (NIST/NIH) database was carried out to obtain a match or a starting point of general 
structure for mass spectrum breakdown analysis. This mass spectrum analysis was conducted to 
insure the fragment breakdown was plausible for the predicted pyrolytic compound, and the 
chromatography was evaluated via retention index (RI) where possible. This combined data 
analysis along with a logical mechanism of production via pyrolysis was used to predict 
compound identifications, and these were confirmed with reference materials where available.  
3.3 Results 
3.3.1 Methamphetamine 
The pyrolysis of methamphetamine produced five products Figure 3.1. Among these 
products are both previously found and newly observed pyrolytics. The amphetamine was 
confirmed with reference standard, while the others were identified by an obtained NIST 
database match of at least 75 and reasonable mass spectrum analysis. Amphetamine, N-formyl-
methamphetamine and N,N-dimethyl-amphetamine were identified in previous studies spanning 
from the late 80’s into the 2000’s, which are described in the review paper by Nida and Bell
1
. 
Amphetamine is a central nervous stimulant as well as N,N-dimethylamphetamine, which may 
produce an increased effect on the user when smoking methamphetamine. Pharmacodynamic 
information of N-formyl-methampetamine is lacking and in need of investigation. On the other 
hand, N-acetyl-methamphetamine and N,N-dimethyl-phenethylamine have not previously  been 
reported as thermal degradation products of methamphetamine. The acetylated product, 
compound 4 from Figure 1, has been thought to be an impurity in illicit drug synthesis, but now 
appears to be the product of a pyrolytic acetylation process, which could further break down into 
previously reported compounds, 1, 2 and 3
28
. Breakdown of compound 2 could lead to the 
production of N,N-dimethyl-phenethylamine via demethylation, which is known to be a 
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Figure 3.1 – Proposed pyrolytic breakdown of methamphetamine into five pyrolytic 
products. M = Methamphetamine metabolite; P = Previously found pyrolytic product 
stimulant and mood enhancer used as a flavoring agent. The production of N,N-dimethyl-
phenethylamine through the smoking process could enhance the effect and thus increase the 
potential for dependence and addition. These compounds would also follow their own metabolic 
and excretion pathways.  The para- location on the benzene ring is a common location for 
possible hydroxylation between each structure, but the additional methyl, aldehyde or ketone 
groups in compounds 2-5 may produce further binding properties as well as supplementary phase 
I and II reaction sites. These metabolites would be missed under current assays, as their ion 
transitions would differ from commonly monitored transitions in methamphetamine urine 
analysis. 
3.3.2 Cocaine 
In the late 80’s, cocaine pyrolysis began to be examined and two major products 
identified were benzoic acid and anhydroecgonine methyl ester, AEME
29-30
. The current study 
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Figure 3.2 – Proposed pyrolytic breakdown of cocaine into eight pyrolytic products.  M = 
Cocaine metabolite; P = Previously found pyrolytic; M* = Metabolite of a previously 
reported cocaine pyrolytic product 
 
also observed and confirmed these two pyrolytic products, while the others were identified using 
the NIST database and mass spectrum analysis. Compound 1 is a predicted product based on an 
equivalent mass spectrum of tropinone except for the parent peak being 17 Da smaller. This 
difference could be explained by the loss of the carbonyl group of tropinone to produce 
compound 1. Along with AEME and benzoic acid, two other reported degradants from a 2007 
study were present, cocaethylene and norcocaine
31
. AEME has been reported to induce greater 
neurotoxicity than cocaine in a 2012 study, which indicates that other pyrolytics may also 
produce added acute toxic effects compared to the parent drugs
32
. Cocaethylene and norcocaine 
have been reported as biomarkers in hair for cocaine abuse, but not directly linked to abuse by 
smoking
33-34
.  Four previously unreported products were detected in the current study, which are 
outlined in Figure 3.2. Of the newly reported products, two tropinone compounds, 1 and 3, are 
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possibly further degradations of earlier observed products. Tropinone is a precursor to atropine, 
an efficacious medication for some nerve agents, and its toxicology is not entirely understood, 
though is considered a level 2 health risk
35
. Compound 1, 8-methyl-nortropidine, is a reduction 
of tropinone, whose pharmacodynamics effects are unknown. Ecgonine methyl ester, another 
newly discovered pyrolytic product is typically seen as a metabolite of cocaine along with a 
number of the other detected products, including compounds 4 and 5. Ecgonidine has been 
described as metabolic product of the pyrolytic product, AEME, and thus has been useful as a 
marker for inhalation as the mode of ingestion when present
36
. The current study supports that 
ecgonidine is a useful smoking marker, but it now may be present even without the necessary 
breakdown of other products. The degradants shown here all have multiple sites for metabolic 
processes, and extensive studies would be necessary to identify possible metabolites. More 
importantly, the numerous products observed provide a basis for toxicological assays and target 
compounds in the analysis of drug paraphernalia. 
3.3.3 Heroin 
Extensive studies on heroin pyrolysis were conducted in the late 80’s and revisited in the 
early 2000’s. In the 80’s, four predicted pyrolytic products were observed including compounds 
2, 3 and 7 from Figure 3.3
37
. These three compounds are produced via acetylation processes at 
the amine chain and phenanthrene ring. Most notable is 6-monoacetylmorphine (6-MAM), which 
is the major metabolite of heroin and the targeted marker for the use of heroin in comparison to 
morphine. The remaining two have largely been unstudied and unconfirmed, but here, a 
proposed GC/MS spectral fragmentation pattern of compound 2 is shown in Figure 3.4. 
Sequential deacetylation and dehydration steps are predicted at steps A - D2. At steps D1, E and 
F, the breakdown of the ethanamine side chain takes place. The 236 m/z species is a predicted 
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Figure 3.3 – Proposed pyrolytic breakdown of heroin into eight pyrolytic products. M = 
Heroin metabolite; P = Previously found pyrolytic; M^ = Metabolite of a newly reported 
pyrolytic product of heroin 
intermediate produced as the dehydrogenation of the position 9 hydrogen of the phenanthrene 
ring and the ethanamine side chain cleavage is initiated. Compounds 1, 4, 5 and 7 were able to be 
confirmed with reference standards. 
Brenneisen and Hasler studied heroin pyrolysis through the inhalation method commonly 
termed “smoking the dragon”, where they observed similar products including another major 
breakdown compound, morphine
38
. In addition to these previously detected products, three 
additional products were observed including two tentatively identified: normorphine and 
nalorphine, and one confirmed: codeine. Normorphine is the major metabolic product of 
morphine, but has little opioid activity
39
. On the other hand, nalorphine is a mixed agonist-
antagonist at the opioid receptors, and produces side effects such as dysphoria, anxiety and 
hallucinations
40-41
. The third newly observed pyrolytic is codeine. A significant consequence of 
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Figure 3.4 – Proposed fragmentation pattern of N,3-O,6-O-triacetylnormorphine, compound 
2 from Figure 3.3. 
 
the observed opioid thermal degradants is the vast difference in half-lives in comparison to 
heroin. Heroin has a rapid half-life of a few minutes, but the thermal degradants may lead to a 
longer duration of action as the additional opiate breakdown compounds, such as nalorphine, 




In the late 90’s, fentanyl, an extremely potent opiate, become a popular drug of abuse and 
has recently been a large part of the opioid epidemic with its lacing of heroin street samples. 
During the 2000’s, a few pyrolysis studies were conducted, which determined that fentanyl is 
thermally stable up to approximately 500°C, but at higher temperatures, pyrolytic products began 
to be observed
45-46
. In Figure 3.5, there are a number of these products that were also identified 
in the current study, shown as compounds 1, 2, 4 and 6, with 2 and 6 being confirmed. 
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Figure 3.5 – Proposed pyrolytic breakdown of fentanyl into six pyrolytic products.               
M = Fentanyl metabolite; P = Previously found pyrolytic 
Despropionyl fentanyl is also a metabolic product of fentanyl as well as a common precursor in 
fentanyl synthesis, but the pharmacologic activity of this compound is thought to be lower than 
that of the parent
47
. Another earlier noted compound also observed here is 1-phenethylpyridium 
(1-PEP), though has not been confirmed via reference standard in any of the studies
46
. The next 
consistently observed pyrolytic between studies is compound 2, N-phenyl-propanamide, which is 
also known as propionanilide. Propionanilide has been reported as a possibly harmful agent if 
orally consumed as noted by the international Globally Harmonized System of Classification and 
Labelling of Chemicals (GHS)
48
. Two newly found pyrolytics were tentatively identified and 
include the methyl ester of propionanilide and bibenzyl. GHS labels bibenzyl as a category 1 
chemical if entered into airways, which is a pertinent danger to any user and bystanders who may 
inhale the vapors
49
. The last major product observed was norfentanyl, which is both a previously 
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detect pyrolytic as well as an observed metabolic product of fentanyl
1
. It has been reported that 
the ratio of fentanyl to norfentanyl can be beneficial in determining if there was an acute fentanyl 
toxicity or chronic fentanyl utilization
50
. This ratio is believed to be >8 for acute toxicity, but this 
value is based on a route of ingestion other than smoking. This would need to be evaluated with 
smoking to ensure confidence in diagnosing acute toxicity in such instances. This is just one of 
numerous areas of impact where fully understanding the smoking process is necessary. 
3.4 Discussion 
Due to differing toxic effects seen in users of the same drug but with different routes of 
ingestion, it had been hypothesized in the past that the abuse of a drug may become more toxic 
when smoked in comparison to other routes of ingestion. An example of this is HSL and had 
been briefly examined. Research in this area had begun to lose interest due to an absence of 
necessary instrumentation capabilities and limited results. The idea has been rejuvenated with an 
investigation of the pyrolysis with synthetic cannabinoids as their acute toxicity is not 
understood, and led to a revisit of these still abused classical drugs. The production and ingestion 
of additional compounds unbeknownst to the user could be a cause of the further toxicity, and a 
complete understanding of the scope of thermal degradation is vital. The knowledge of the 
presence of specific pyrolytic products allows for toxicity evaluations, a larger analyte pool for 
drug investigations and novel metabolic investigations, which may affect current timelines used 
to estimate dosage events.  
The first impact to consider is the pharmacologic effects and toxicity the identified 
products may induce. This concept is supported by the high mortality rate of heroin smokers due 
to HSL in the 1980’s. As the thermal degradation products are identified, the evaluation of their 
toxicity and their individual impacts can be researched. The thermal degradants can be smaller in 
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size and more lipophilic, which both could increase the compounds ability to enter the blood 
stream and interact with receptors throughout the body. The same receptors as the parent drug 
may be the sites of action, but depending on the structure of the degradant, they may interact 
differently and in new sites. Studies on the prevalence of the thermal degradants to be ingested, 
binding affinity evaluations and toxicological assays are interesting avenues of research that stem 
from the knowledge of the re-confirmed and newly identified products. 
Another advantage of knowing these products to consider is within drug investigations. 
Drug paraphernalia collected as evidence can now be further processed. If a drug was smoked in 
set paraphernalia, it is unlikely that the parent compound would remain, but the thermal 
degradants may be left behind. After this report, more analytical targets are available for the 
processing of such evidence with simple collection and analysis techniques that common 
laboratories could implement. Detection of the pyrolytic products may give investigators a 
starting point for their investigations, and may lead to the request of the appropriate toxicological 
testing, as not all precincts may have the monetary ability for wide spectrum testing. Having 
additional information at their disposal, more options will be available to use to decipher 
appropriate actions and conclusions within both criminal and public health cases. 
An interesting finding is the presence of metabolic products as thermal degradation 
products. This can have a resounding effect on the interpretation of toxicological assays. 
Metabolites are typically used as markers of a parent drug and based on studied pharmacology, a 
dosage time and concentration can be extrapolated. However, if these products are produced at 
the dosage event via smoking, this affects how those interpretations can be made. Secondly, the 
thermal degradants open the possibility for additional sites for phase I and II metabolism, and 
will have unique metabolic products. As metabolic profiles can be established for the thermal 
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degradants, these metabolites may be detected for a longer time period and be used as additional 
markers for the smoking of a drug compound. The pharmacologic data of the thermal degradants 
will have to be added to current knowledge of parent drugs for accurate dosage estimates as well, 
as the concentration of known metabolites is no longer zero, but the amount of the compound as 
a pyrolytic that is ingested along with the parent.  
3.5 Conclusion 
The current study has reconfirmed the production of many thermal degradants that had 
been previously reported as well has detected a number of newly observed pyrolytics using the 
methodology previously reported. The observed products can be useful in analyzing drug 
paraphernalia, provide novel target analytes in toxicological assays and affect the interpretation 
of currently monitored metabolites. As more products are identified, numerous research 
opportunities will arise to understand the rate of ingestion, pharmacology, metabolism and 
toxicity of each thermal degradant. 
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Chapter 4: Detection of Confirmed Thermal Degradation Products 
of Ten Synthetic Cannabinoids in Post-Mortem Blood Samples 
 
This chapter is an adaption of a submission to the Journal of Forensic Toxicology in April 2018. 
Detection of Confirmed Thermal Degradation Products of Ten Synthetic Cannabinoids in Post-
Mortem Blood Samples. S. Raso and S. Bell. 
Permission will be obtained from the co-authors and the Journal Forensic Toxicology according 
to the journal’s license’s, copyright and permissions policy. A copy of the permissions agreement 
will be shown in Appendix A if obtained before submission to the college. 
 
The vast toxic effects of synthetic cannabinoids have proven difficult to counteract and 
fully understand. Adverse effects outside of the common cannabinoid tetrad have been observed 
in multiple body systems with various causes of death. A relevant hypothesis to the current study 
is the overlap of symptoms with serotonin syndrome. Current research has begun to link the use 
of cannabinoids to serotonin syndrome by the finding of thermal degradant products that contain 
similar core structures. This leads to the notion that the cannabinoid pyrolytics may have binding 
activity at the serotonin receptors, in which causes the toxic side effect of serotonin syndrome. 
This report aids in further making this hypothesis a logical possibility. It is the first simultaneous 
monitoring of parent synthetic cannabinoids and possible thermal degradation products in 
postmortem blood samples. A validated LC/MS/MS method following a liquid-liquid extraction 
provided the detection of multiple thermal degradant compounds within the blood samples. The 
establishment of the pyrolytic ingestion into the body indicates that they cannot be dismissed in 
the evaluation of the toxicity of synthetic cannabinoids. The degradants presence may impact 
toxicological assays, metabolic profiles as well as toxic secondhand inhalation of bystanders. 
The results presented here direct the need for research into the activity of such degradants, 
determination of their metabolic profile, further investigation into the possibility of serotonin 
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syndrome, and added testing of postmortem samples for additional pyrolytics as well as 
metabolites, which have been observed in previous work on drug pyrolysis. 
4.1 Introduction 
The prevalence of synthetic cannabinoids is a public health issue due to the diverse toxic 
effects produced. It is challenging to effectively interpret the lethality of synthetic cannabinoids, 
while also responding to usage outbreaks and identifying new generation compounds. Recently 
in New York City, 33 individuals were intoxicated in a single neighborhood, and 18 had to be 
hospitalized
1
. Traditional cannabinoid effects are described using the “cannabinoid tetrad”: 1) 
hypothermia, 2) analgesia, 3) catalepsy and 4) locomotor activity suppression, but adverse 
toxicity beyond this tetrad are seen in multiple body systems with synthetic abuse
2-5
. Acute 
kidney injury (AKI) is one of the effects observed in the endocrine system, and is often seen in 
emergency rooms where synthetic cannabinoid use is coupled with alcohol
6-9
. Cardiovascular 
effects include tachycardia, hypertension, palpitations and even myocardial infarctions
10-14
. 






Figure 4.1 – The structure of serotonin and examples of proposed synthetic cannabinoid 
thermal degradants with similar structure. 
In recent years, it has been suggested that some of the observed toxic effects overlap with 
symptoms of serotonin syndrome
20
.  Serotonin syndrome is caused by an over-abundance of 
serotonin. Numerous symptoms including agitation, confusion, tachycardia and seizures are seen 
to name a few, but is commonly described as a triad of muscular abnormalities, autonomic 
hyperactivity and mental-status changes
21
. It is a potentially fatal sickness, and may be a toxic 
side effect of synthetic cannabinoids
22
. A previous investigation into the thermal degradation of 
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cannabinoids may have provided a missing link to connect cannabinoids to serotonin syndrome. 
Numerous suggested pyrolytic products have contained similar core structures to that of 
serotonin, which could explain the serotoninic effects, and a few examples are shown in Figure 
4.1
23
. The structural resemblance indicates the possibility of equivalent binding capabilities, thus 
the abundance of thermal degradants may produce serotonin syndrome like effects. 
Based on a global survey in 2017, 59.5% of respondents who ingested cannabinoids did 
so in herbal form in comparison to powders, resins and oils. Sixty-six percent of those users 
acknowledged smoking the drug via rolled cigarette
24-25
. Given that smoking primary mode of 
ingestion, an understanding of the thermal degradation process and products is important in the 
larger context of toxic effects. The high temperatures reached during pyrolysis induce complex 
reaction zones where thermal degradation and free radical processes occur. The thermal 
degradation of a compound produces any number of supplementary compounds to the parent 
itself. Since pyrolysis is a free radical environment, unique reactions are possible including ring 
expansions, which are an indication of a pyrolytic process. An evaluation of pyrolysis on illicit 
drugs over time via a literature review was conducted in 2014 with intriguing results and 
limitations to the performed studies
26
. Subsequent work by our group has developed a novel 
smoking simulation apparatus and pyrolysis method to resolve the apparent limitations and 
applied it to synthetic cannabinoids and classical drugs of abuse
23
. 
 A notable finding of these studies was the formation of metabolites by thermal 
degradation. Metabolite presence is influential evidence to the use of a particular drug. Current 
pharmacokinetic models are based off the production of metabolites after the time of ingestion, 
but this interpretation must be altered if the metabolite is present at the time of exposure within 
the inhaled vapor. It is also important to take into account the activity of the metabolic product. 
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As thermal degradants have been demonstrated to be produced, it is crucial to evaluate the 
presence of such products within the body to establish their ingestion along with the parent 
compounds. To date, the two largely detected thermal degradants are the UR-144 and XLR-11 
degradants. A recent study has shown that the UR-144 degradant has a fourfold stronger binding 
affinity at CB1 in comparison to the parent drug
27
. The UR-144 degradant has also been detected 
in blood as well as its predicted metabolites in urine
28
. The XLR-11 degradant was also found to 
have its own metabolic profile as the analysis of a known user’s urine produced metabolites 
varying from the parent’s profile
29
. However a small sample size, a clear precedent for thermal 
degradants being ingested is set, as these products would not be produced metabolically after the 
ingestion of solely the parent drug. 
This report is the first to the author’s knowledge of a comprehensive study of postmortem 
blood samples for broad spectrum monitoring of thermal degradation products with known 
parent drug presence. The obtained blood samples were previously analyzed and found to 
contain one or more synthetic cannabinoids. Based on the known cannabinoid the detection of 
predicted pyrolytic products was carried out using a validated and optimized LC/MS/MS 
method. The results of the study demonstrate that the presence of thermal degradants, including 
those with ring expansions only produced at high temperatures, and cannot be dismissed. Further 
research is significant as these products will produce their own unique metabolic and 
pharmacodynamics profiles. 
4.2 Methods 




Each of the solvents used for liquid chromatography analysis including water with 0.1% 
formic acid and acetonitrile with 0.1% formic acid were obtained from Thermo Fisher Scientific 
(Waltham, MA). The extraction solvents, 0.2M sodium carbonate buffer at pH 9.4, 99:1 hexane-
ethyl acetate and 50:50 methanol-acetonitrile with 0.1% formic acid were prepared using 
solvents from Thermo Fisher Scientific. Synthetic cannabinoid standards of 5F-ADB, 5F-AMB, 
5F-PB-22, AB-CHMINACA, AB-FUBINACA, AB-PINACA, ADB-FUBINACA, FUB-AKB-
48, MAB-CHMINACA and MMB-FUBINACA were purchased from Cayman Chemical (Ann 
Arbor, MI). Standards of predicted possible thermal degradation products were obtained as 
follows: 4-hydroxycinnoline and 3-hydroxyquinoline from Ark Pharm, Inc. (Arlington Heights, 
IL); indazole-3-carboxaldehyde, indazole, indole, quinoline, N-methylindole, 4-methylquinoline 
and indole-3-carboxaldehyde from Sigma-Aldrich Chemicals (St. Louis, MO); 1-methylindazole 
and cinnoline from Alfa Chemistry (Holtsville, NY); pentylindazole, pentylindazole-3-
carboxaldehyde, pentylindole and pentylindole-3-carboxylic acid were synthesized by the Dr. 
Gregory Dudley research group at West Virginia University. Human blood for validation studies 
was obtained from Zen Bio, Inc. (Research Triangle Park, NC). The case sample blood for 
pyrolytic evaluation was provided by NMS Labs (Willow Grove, PA). 
4.2.2 Sample Preparation 
Stock standard solutions of synthetic cannabinoids were prepared at 1 mg/ml in either 
methanol (MeOH), acetonitrile (ACN) or a 50:50 mixture of MeOH-ACN dependent on 
solubility and stored at -20°C. Working solutions were prepared by serial dilution at 
concentrations of 10000, 1000, 100, 10, 1, 0.1 and 0.01 ng/ml. A 0.2M sodium carbonate buffer, 
pH 9.4 was prepared by mixing the contents of a BupH
TM
 carbonate-bicarbonate buffer pack to 
500 ml of degassed, deionized water. 
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4.2.3 Blood Extraction 
To 1 ml of drug-free blood, 200 µl of working synthetic cannabinoid solution was added 
to obtain the desired concentration. Five hundred microliters of 0.2M sodium-carbonate buffer, 
pH 9.4, was added and vortexed for 20 s followed by the addition of 1.5 ml of 99:1 hexane-ethyl 
acetate. The samples were mixed for 20 min followed by a 10 min centrifugation. The top 
organic layer was transferred to a clean vial, evaporated under nitrogen gas at 40°C, reconstituted 
in 200 µl of mobile phase (50:50 MeOH-ACN with 0.1% formic acid), and transferred to a 




4.2.4 Instrumental Analysis 
The chromatographic analysis for this study was carried out using a Shimadzu (Houston, 
TX) prominence high performance liquid chromatograph (HPLC) coupled with an AB SCIEX 
3200 QTRAP LC-MS/MS (Framingham, MA) system equipped with a Turbo V
TM
 source. The 
LC was comprised of a DGU-20A3R degasser, LC-20AD pump, SIL-20AC HT autosampler and 
CTO-20AC oven. Analyst software 1.6.3 was used for data acquisition and analysis. 
 For chromatic separation, a Phenomenex Kinetex C18 analytical column (30 x 2.1 mm ID 
x 2.6 µm) was utilized (Torrance, CA). The oven compartment was held at 40°C, and the 
injection volume was 5 µl. A gradient elution program was developed with water with 0.1% 
formic acid (mobile phase A) and ACN with 0.1% formic acid (mobile phase B) with a flow rate 
of 0.5 ml/min. The conditions of the gradient were: starting conditions 20% B and held for 0.3 
min, increased to 40% B at 2.3 min, ramped to 50% B at 12.3 min, ramped to 70% B at 14.3 min, 
returned to 20% B at 15.3 min and held for 0.6 min for a total run time of 16.0 min. Baseline 
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resolution was not fully achieved, but the target analytes had different transition, which allowed 
for accurate compound determination. 
 The mass spectrometer was operated in positive mode with electrospray ionization (ESI) 
and MRM acquisition. The source dependent parameters during analysis were: GS1 gas was set 
at 10 psi, GS2 at 0 psi, CUR (curtain) at 10 psi, CAD (collision cell) at medium, IS (ion spray 
voltage) at 5,500 V and no heat was applied to the source. Two MRM transitions were monitored 
for each optimized compound. The optimized compound dependent parameters were determined 
by direct-infusion analysis with a flow of 10.0 ml/min. The parameters that were optimized 
included declustering potential (DP), entrance potential (EP), collision cell entrance potential 
(CEP), collision energy (CE) and collision cell exit potential (CXP). The MRM transitions and 
optimized parameters for each pertinent compound are listed in the supplementary material; 
Appendix C. Additional compounds were optimized and monitored as possible pyrolytics, but 
were omitted from Table C1 due to not being observed in the blood sample analysis. 
Additionally, a standard of 4-methylcinnoline was unavailable, so the transition masses are 
predicted based on the obtained product ions of cinnoline, and the compound dependent 
parameters were kept the same as cinnoline due to the minor difference of a methyl group in 
structure. 
4.2.5 Method Validation 
The goal of this study is to observe thermal degradation products in a qualitative manner, 
however, a number of parameters were validated for the adapted methodology based on a 
previous report and SWGTOX guidelines including linearity, limit of detection (LOD), limit of 
quantitation (LOQ), within-day and between-day precision, accuracy, extraction recovery and 
matrix effects. The linearity was determined by analyzing a multiple concentration calibration 
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curve over 10 consecutive days. The linear relationship of the minimum six point curve was 
evaluated by calculating the regression via the least squares method. The determined R
2
 values 
were required to be 0.990 or better. The LOD and LOQ were determined based on back 
calculating each sample concentration with the generated curve and comparing it to the 
theoretical concentration. A level of acceptance was set at ±20%. The LOD was defined as the 
lowest analyzed concentration at which the relative retention time was within 3% and produced 
consistent signal intensity, while the LOQ was defined as the lowest concentration that met the 
set ±20% criteria. 
 The instrument precision and accuracy was evaluated at low, middle and high 
concentrations within the linearity range of 10, 100 and 1,000 ng/ml respectively. The within-day 
precision was determined by analyzing 5 aliquots of a single extraction. The between-day was 
evaluated over a 10 day period of a single aliquot. The precision acceptance value was set at a 
coefficient of variance (CV) or ≤ 20%. As for the accuracy, it was defined as the percent 
difference of the average calculated concentration and the theoretical fortified concentration. For 
acceptance, the percent difference was required to be ≤ 20%.  
 Extraction recovery and matrix effects were evaluated at both a low and high 
concentration within the linearity range of 50 and 500 ng/ml respectively, in triplicate. For each 
examined compound concentration pair, three samples were generated. Sample 1 consisted of the 
analyte of interest in the extraction solvent. Sample 2 was a pre-extraction sample produced by 
fortifying reference standard into blank blood and then extracting as previously described. 
Sample 3 was the post-extraction sample made by adding reference standard after extraction but 
before the evaporation process. Using these samples, the extraction recovery was determined by 
the sample 2 response divided by the sample 3 response. The matrix effect was defined as the 
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sample 3 response divided by the sample 1 response. A value of over 100% indicates ion 
enhancement, while values under 100% indicate ion suppression.  
4.2.6 Blood Analysis  
Case blood samples were obtained along with the identification of the parent synthetic 
cannabinoids that were detected during analysis. These identifications are outlined in Table 4.1, 
and the structures are shown in Figure 4.2. Each compound has an equivalent indazole core 
structure except 5F-PB-22, which is indole based. Such information was used to predict the 
thermal degradation products to monitor for in this project, and it is important to note that due to 
similar structural make-up, they could produce common products. The volume of blood per 
sample varied from approximately 1-5 ml, and each extraction analysis was carried out on 1 ml 
portions via the methodology previously described. Where applicable each sample was extracted 














        Table 4.1 – Previously detected synthetic cannabinoids within the case blood samples 
        obtained and reported from NMS Labs 
Description Sample Number Compound 
Single Drug 
1 AB-PINACA 
2, 21 AB-FUBINACA 
3, 17 MAB-CHMINACA 
4, 18, 22, 23 ADB-FUBINACA 
5, 6, 7, 9, 10, 13, 16, 19 5F-ADB 
8 MMB-FUBINACA 
14 5F-AMB 





































4.3.1 Method Validation 
Linearity was assessed using eight concentrations ranging from 0.01 – 1,000 ng/ml 
comprised of 0.01, 0.1, 1, 10, 25, 50, 100 and 1,000 ng/ml standard concentrations. The 8 
concentrations were necessary as the low end concentrations were not consistently observed and 
at least six points were desired for the calibration curves. The linearity was found to be 




acceptable across the analyzed concentrations for each compound based on the produced 
calibration curve R
2
 values. The LOD was commonly observed to be approximately 1 ng/ml but 
as low as 0.01 ng/ml. As for the LOQ’s, they ranged from 1 – 10 ng/ml. The experimentally 
obtained values for each compound are summarized in Table C2. 
 The within-day and between day precision and accuracy were evaluated at a low, mid and 
high concentration across the linearity range, and chosen levels were 10, 100 and 1,000 ng/ml. 
All within-day and between-day precisions were acceptable with the exception of the 1,000 
ng/ml samples of AB-PINACA being scarcely unacceptable with CV values for between-day and 
within-day of 20.5 and 20.7% respectively, and the 1,000 ng/ml between-day sample for FUB-
AKB-48 and 100 ng/ml within-day sample of 5F-ADB at 20.9 and 20.3 respectively.  The 
between-day accuracies were accepted with the exception of MMB-FUBINACA at 100 ng/ml 
with a percent difference of 21.9%. The between-day accuracies all fell under 20%. The data of 
all calculated precision and accuracy values are detailed in Table C3. 
 The extraction efficiency and matrix effects were evaluated at two concentrations, 50 and 
500 ng/ml, which were a low and high concentration value within the linear ranges. The 
corresponding data is within Table C4. The extraction recoveries ranged from 64.7 – 165.16 %. 
The extraction protocol was taken from a previous report, which had a recovery range of 70 – 
174 %
30
. The recoveries reported here are comparable with a slightly smaller overall range. The 
matrix effects were determined to range from 41.91 – 155.71 %, which again was comparable to 
the previous report as their reported range was 27 – 147 %
30
. The majority of the samples were 
under 100%, indicating ion suppression, but when ion enhancement was observed, it was at a 
much larger rate. Twelve of the 30 total samples, nearly half were within ± 20 %, showing little 




4.3.2 Blood Analysis 
The samples were analyzed up to three times dependent on the amount of blood supplied. 
Thermal degradation products were detected in each sample except one, which may have been 
due to the small volume of blood obtained or due to the user not ingesting the drug compound 
via a smoking process. Six compounds were consistently observed at a signal level of greater 
than three times the noise level. The results and structures of the observed pyrolytic products are 
outlined in Table 4.2 and Figure 4.3. Each contained either the core indazole ring or the 
expanded ring form of indazole, cinnoline, which is a process indicative of pyrolysis. From the 
samples containing a single drug, 4-hydroxycinnoline, 1H-indazole-3-carboxaldehyde and 
cinnoline were commonly observed, which is emblematic of each parent drug containing 
structurally similar cores. The pyrolytic products observed within the mixtures are consistent 














Table 4.2 – Observed thermal degradation products from the case sample blood samples. 
1: 4-Hydroxycinnoline; 2: 1H-Indazole-3-carboxaldehyde; 3: Indazole; 4: Cinnoline;      
5: N-  Methylindazole; 6: 4-Methylcinnoline; 7: N-Pentylindazole. *- Not Confirmed 




1 and 2 6 of 8 
4 and 5 4 of 8 
6* 3 of 8 
7 1 of 8 
5F-AMB 1, 2 and 4 1 of 1 
AB-FUBINACA 
1 and 2 2 of 2 
3 and 4 1 of 2 
AB-PINACA 1 and 2 1 of 1 
ADB-FUBINACA 
1 and 2 4 of 4 
4 1 of 4 
MMB-FUBINACA 1, 2 and 7 1 of 1 
  Compounds TD(s) Observed 
Mixtures 
5F-ADB         
MMB-FUBINACA 
N/A 
AB-CHMINACA    
FUB-AKB-48   
MAB-CHMINACA 
1 and 2 
5F-PB-22            
AB-CHMINACA    
FUB-AKB-48   
MAB-CHMINACA 
1, 2 and 6* 
5F-ADB             
ADB-FUBINACA 

















As the results of the current study began to evolve, a review of unwanted factors was 
conducted. The assurance of the pyrolytics being present within the blood itself and not produced 
through analysis, specifically the electrospray ion source (ESI), was confirmed as the degradants 
eluted at different times than the parent compounds. If they were produced within the ESI, the 
retention times would be equivalent as the ESI is applied after the chromatography. The 
collection time of the blood relative to the ingestion time is unknown, so it is understood that 
additional pyrolytics may have been present and already undergone metabolism. Urine analysis 
would need to be carried out to fully understand the spectrum of degradants and their metabolites 
that may be present for toxicological assays, along with a time course for such breakdown. 
Nineteen of the 23 blood samples contained a single drug compound, and in comparing 
the results within samples containing the same drug, a few patterns are apparent. Each of the 6 
parent cannabinoids produced both 4-hydroxycinnoline and 1H-indazole-3-carboxaldehyde. 
Cinnoline was present in samples of 4 of the 6 parent cannabinoids, which is the other 
predominantly observed pyrolytic. The remaining 4 degradants seen were more sporadic and 
typically in a relatively lower abundance. The greater abundance and more consistent production 
of degradants 1, 2 and 4 is to be expected based on the predicted breakdown of the parent 
cannabinoids. The amine bond located within the indazole ring and the amide group would be 
expected to cleave as carbon-nitrogen bonds are relatively weak. This process would produce 
compound 2, and then a ring expansion process of the indazole ring allows for the production of 
compound 1. Lastly, the dihydroxylation of compound 1 would produce compound 4.  
 The data analysis of the single drug samples also provided some anomalies. There were 8 
samples containing solely 5F-ADB, but two samples did not appear to produce all of the same 
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degradants as the other 6. Samples 13 and 16 produced only compound 6, 4-methylcinnoline. It 
is first important to note that both of these samples had a small volume of blood and were only 
able to be analyzed once. The presence of compound 6 in general was interesting as it was never 
observed in samples where compound 4, cinnoline, was present. These degradants differ by only 
a methyl group, and as previously described, the MRM of 4-methylcinnoline was predicted 
based off of the cinnoline optimized parameters. Further confirmation of 4-methylcinnoline is 
necessary to definitively determine if in fact both compounds are present or just one. As for AB-
PINACA, 5F-AMB and MMB-FUBINACA, there was only one single drug sample, thus further 
replicates of these is desired to support the observed products, but the observed thermal 
degradants is understandable based on the resemblance between them and the other parent drugs 
analyzed. 
 The thermal degradants within the mixtures appeared to coincide with those observed 
within the single drug samples, with the exception of sample 11, which produced no results. 
Sample 11 had less than 1 mL of blood, which may have had an effect on the lack of pyrolytic 
product detection, and additionally, the user may have not smoked the drug as the route of 
ingestion. Sample 12 contained AB-CHMINACA, FUB-AKB-48 and MAB-CHMINACA, 
which were not amongst the single drug samples. Compounds 1 and 2 were detected and justified 
as these cannabinoids differ in structure of substituent groups, not the core structure producing 
such degradants. However, it cannot be confirmed which compound may have produced the 
degradants or if each did individually. Sample 15 contained the most diversity of cannabinoids, 4 
different compounds. As in sample 12, the degradants could be present due to any of the parent 
cannabinoids incorporated in the sample except for 5F-PB-22. This is the only instance of 5F-
PB-22, but at this time it cannot be stated that it provided any of the current pyrolytics as it 
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contains an indole base versus the indazole base presently detected. Further analysis into 5F-PB-
22 and other indole based cannabinoids may yield thermal degradants not observed here. The 
final mixture, sample 20, contained 5F-ADB and ADB-FUBINACA, which were the two 
cannabinoids analyzed as single drugs at the highest rate. Degradant compounds 1, 2, 4 and 5 
were detected. Compound 5 had not been detected in the ADB-FUBINACA samples, and is 
perceived to be produced by 5F-ADB, while the other 3 could be present due to either compound 
or both. 
 It is challenging to unambiguously define what makes two compounds “similar” to one 
another, but for the purposes of this discussion, the detected pyrolytics are deemed “similar” to 
serotonin based on their structural base. Serotonin consists of an indole ring structure with an 
alkyl amine chain and a hydroxyl group. The seven thermal degradants described here contain 
either an indazole or cinnoline ring base. These differ from the serotonin indole base by only a 
substitution of nitrogen for carbon in indazole or a single carbon increase in ring size. It is 
plausible that these base ring structures would interact with the same receptor binding sites as 
serotonin. Their presence could then be a factor in the symptoms that overlap with serotonin 
syndrome. 
4.5 Conclusion 
The detection of various thermal degradant products in the current study demonstrates the 
necessity for further research into their activity, metabolism and possible toxicity. They cannot 
be dismissed as a frivolous exploration. This report coupled with previous reports clearly 
establishes not only the production of pyrolytic products, but their ingestion by a user while 
smoking such cannabinoids. The findings presented here also take the next step in connecting 
cannabinoids to the possible toxic side effect of serotonin syndrome. It is now established that 
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numerous degradants with similar core structures to serotonin are not only produced, but also are 
ingested by the user. As their presence in the vapor is known, innocent bystanders may also 
ingest the pyrolytic products. Further research endeavors in this area may aid in answering some 
relevant issues created with synthetic cannabinoids. 
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Chapter 5: Conclusions and Future Directions 
 
5.1 Impact of Conclusions 
 This study has successfully identified numerous thermal degradation products for a 
representative group of synthetic cannabinoids, established a predictive model for forecasting 
thermal degradation products of cannabinoids not yet analyzed, validated an LC/MS/MS method 
for a collection of synthetic cannabinoids and detected a number of thermal degradants within 
post mortem blood samples. The current research has reiterated the lack of knowledge in the 
field of drug pyrolysis, and demonstrates a strong proof of concept insight to open discussion 
into the effect of thermal degradation products on the toxicological effects of synthetic 
cannabinoids. 
 The first phase of this project developed a novel approach to mimicking a smoking 
process while utilizing an exhaustive sample collection method for the pyrolysis of synthetic 
cannabinoids. The results of the pyrolysis studies unveiled that a single synthetic cannabinoid 
may produce up to 10 – 15 thermal degradation products. The observed predicted products 
contained compounds that share core structures to previously known toxic compounds. The 
pyrolytic products may produce similar toxicity to users upon inhalation as well as bystanders 
whom may inhale the produced vapors. 
 Following the demonstration of thermal degradation product formation, to provide a 
supported possibility of such products being toxic, they must first be proven to be ingested. True 
case sample post mortem blood was obtained to evaluate the presence of thermal degradation 
products. The set of synthetic cannabinoids present within the blood samples were previously 
identified, and a new LC/MS/MS method was validated for the aforementioned cannabinoids 
86 
 
after optimization of all pertinent compounds. Prior to the current study, only two thermal 
degradants have been detected in toxicological specimen. This study expands the thermal 
degradants detected in post mortem samples, and supports the need for continued research 
investigations into the metabolism, binding activity and toxicity of set products. 
 Fields of forensic science including drug analysis, toxicology assays and medicolegal 
investigations can profit from the results of this study. Drug paraphernalia can be analyzed for 
degradant products left behind to establish a basis for the investigation as certain markers may 
indicate the use of particular drug compounds. The thermal degradation products are also 
markers in toxicology specimen to indicate that the mode of ingestion was smoking or 
inhalation. Lastly, as effects of the thermal degradants are defined, the gained knowledge will be 
impactful on medicolegal assessments. 
5.2 Future Directions 
 As this was the first broad monitoring of pyrolytic products in post mortem blood, 
additional studies for the identification of more pyrolytics should be conducted. As more 
pyrolytic products are identified, the compounds can be added to monitoring assays and 
evaluated for their presence as well. Post mortem samples must be continued to be evaluated for 
not only the parent cannabinoids, but their pyrolytic products too. After the determination of 
other pyrolytics utilizing the established methodology, a quantitation step must be developed.  
 As quantitation of pyrolytic products within toxicology specimen is performed, a number 
of important pieces of information may be obtained. First and foremost, it will provide insight 
into the types of pyrolytics that are most commonly ingested and need to be further researched. 
Once the methodology is set, controlled inhalation studies may be conducted to determine a 
percent breakdown of the parent cannabinoid as well as rates of ingestion. This type of research 
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would need to be carried out using mice or rats, as it would be unethical to have human first start 
smoking such dangerous drug compounds. The rates of ingestion could be adapted for an 
estimated value in humans, and provide a number of products that should be evaluated for their 
effects post ingestion. 
 After the thermal degradants are ingested they will have their own metabolic profile. 
Metabolism studies may be carried out on the pyrolytic products that displayed the most promise 
in the ingestion rates studies. The unique metabolites identified from the pyrolytics will offer 
markers for the route of ingestion in urine samples to couple with the parent pyrolytic products in 
blood. The parent cannabinoid compounds are not always present by the time specimen are 
collected, so the additional target analytes provided by the pyrolytic products and their 
metabolites vastly increase the chances of the detection of a marker indicating the use of 
synthetic cannabinoids. 
 Once an encompassing set of target analytes is completed, it would be necessary to 
evaluate their activity within the body. The products may still hold affinity to the cannabinoid 
receptors, or as previously mentioned, a number of pyrolytics may have an affinity for serotonin 
receptors. The overall activity of each product as well as their metabolites would need assessed 
to completely understand how a user may be affected by smoking synthetic cannabinoids. Not 
only is the pharmacology of the products crucial, but also their possible toxicity. Toxicity studies 
should be performed to evaluate if their presence may be one of the causes of the additional 
toxicity observed with synthetic cannabinoids outside of the common tetrad. There is valuable 
information to be gained from further investigation into the pyrolysis of synthetic cannabinoids 
and their thermal degradation products. They cannot simply be dismissed as a non-factor at this 



































Supplementary Material for Chapter 2: Qualitative Analysis and Detection of the Pyrolytic 
Products of JWH-018 and 11 Additional Synthetic Cannabinoids in the Presence of 
Common Herbal Smoking Substrates 
 
 




























Figure B5 – Heating signature of the reaction zone with each herbal material present, and the 
average of all trials indicated by the black dashed line 
 
The first step was to show that the heating signature produced by the propane torch was 
consistent between trials. Evaluation was carried out by placing the end of the torch 
approximately 2 ½” from the T-junction, so that the tip of the inner blue cone of the flame was in 
direct contact with the quartz tube at the reaction zone. This was first carried out with no plant 
material present to allow for observation of the reproducibility of the heating process, and the 
temperature was monitored for 40 seconds in 10 replicate trials. The next step was to add the 
herbal material to ensure burning commenced and that a “smoking-like environment” could be 
established. Twelve pyrolysis trials of the six herbal substrates were performed with a burning 
time of 40 seconds and an n=2 for each species, and the heat signature was monitored.  
The propane torch produced a consistent heat signature as the heat was able to spread uniformly 
throughout the reaction zone. However, the independent herbal matrix pyrolysis trials displayed 
variability. This is due to the dependency on when and how that herbal material ignites and 
burns. The difference between these could be attributed to several hypothesized factors. The first 
is the dependency on where the plant material ignites and how the burning spreads. The 
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thermocouple is centered in the reaction zone, but it is challenging to control the ignition and 
spread across the plant. Thus the proximity to the thermocouple may produce variability in the 
temperature reading between trials. Another possible factor is leaf size and density of the herbal 
substrate, which may cause a difference in actual amount of herbal material present as only the 
mass was held constant. Finally, different heat capacities may contribute as well, but these values 
are unknown. 
 
Table B1 – Proposed identification of products observed in herbal material pyrolysis 













Each of the six herbal species was pyrolyzed in triplicate. If a chromatographic peak was 
observed within +/- 0.05 min, it was deemed to be consistently produced. Ten chromatographic 
peaks were observed and tentatively identified. The tentative identifications of these ten products 
are shown in the table below. The products observed were consistent with previous plant matter 
pyrolysis studies. These studies have been conducted on different plant species, but display 
precedence of the varieties of compounds expected through the pyrolysis of plant material. In the 
1970’s, it was reported that plant pyrolysis produces a myriad of phenol and methoxyphenol type 
compounds and a study by Boon et al reported a major product of the Scirpus species to be 4-
vinyl-phenol, supporting reports of phenol-like pyrolytic products
1-4
. Cellulose is a large part of 
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plant structure and degrades into several compounds, but one in specific is 1,6-anhydroglucose, 
which further breaks down into furan-like compounds
5-6
. Recent studies support furan-like 
product findings such as a 2005 study on tobacco pyrolysis, where the presence of phenol, 
pyridine, cresol, benzofuran, and dihydrobenzofuran were reported
7
. Two products observed in 
this paper, oleanitrile and oleamide, initially seemed surprising, but two recent studies show 
otherwise. Heo et al have shown that oleamide is present in many plant species, one specifically 
Ziziphus jujuba, and just this year, Jin et al shows that oleanitrile is present in at least the plant 





Figure B6 – Schematic of the exhaustive sampling of JWH-018 on Damiana to optimize the 
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Supporting data and side project conducted, but not included in the chapter 2 manuscript. 
 
Percent Recovery Study of Pyrolysis Methodology: 
The samples for pyrolysis on the herbal matrices were prepared by spraying the drug 
compound solution onto the matrix before allowing the solvent to evaporate to leave the drug 
behind. To evaluate the percent recovery, it was necessary to take the process step by step to 
determine any observed loss. As this project would eventually reach pyrolysis recovery, caffeine 
was chosen for this study because of its thermal stability. At this stage, breakdown was undesired 
to allow for quantitation of a single signal. Caffeine-d3 was used as an internal standard for 
quantitation. Establishing a known amount of drug sprayed onto sample was essential, and the 
first step was to determine the volume of solution dispensed per spray to allow for accurate 
concentration control.  
This was examined by two methods. Both methods utilized the monitoring of weight 
difference to equate to volume using the density of water. Method 1 was to take the average 
weight difference of 10 sprays with 10 replicates. The data for this method is shown below in 
Table C1. Method 2 was to find the mass difference of each spray over the span of 25 sprays. 
The number of sprays was plotted vs the volume added, and the best fit line was found. The 
slope of this line is observed as the volume added per spray. The data and plot for method 2 are 
shown in Table C2 and Figure C1. Method 1 gave a volume per spray of 0.0421 ±0.00139 ml, 
and method 2 produced a volume of 0.0403 ml, which is slightly outside the range of method 1 




Table C1 – Data for method 1 of the determination of volume per spray of the sprayer used for 
sample preparation. * : Density of water used was 0.9982 g/ml due to a 20°C environment 
Initial Mass (g) Final Mass (g) Mass H2O Added (g) Volume H2O Added (mL)* 
10.07509 10.46708 0.39199 0.3927 
10.46708 10.89499 0.42791 0.4287 
11.05308 11.50102 0.44794 0.4487 
11.50102 11.92302 0.422 0.4228 
11.92302 12.33440 0.41138 0.4121 
12.33440 12.75682 0.42242 0.4232 
12.75682 13.17491 0.41809 0.4188 
13.17491 13.59617 0.42126 0.4220 
13.59617 14.01287 0.4167 0.4175 
14.01287 14.43478 0.42191 0.4227 
  
  
Avg. Vol. of 10 
sprays = 
0.4209 
Std. Dev. =  0.0139 
  
Avg. Vol. per spray = 0.0421 




















Total H2O Mass 
Added (g) 
Total Volume H2O 
Added (mL)* 
0 14.43204 0 0 
1 14.47436 0.04232 0.0424 
2 14.51576 0.08372 0.0839 
3 14.55515 0.12311 0.1233 
4 14.59753 0.16549 0.1658 
5 14.63892 0.20688 0.2073 
6 14.67970 0.24766 0.2481 
7 14.72175 0.28971 0.2902 
8 14.76194 0.3299 0.3305 
9 14.80091 0.36887 0.3695 
10 14.84014 0.4081 0.4088 
11 14.88021 0.44817 0.4490 
12 14.91791 0.48587 0.4867 
13 14.95873 0.52669 0.5276 
14 14.99902 0.56698 0.5680 
15 15.03883 0.60679 0.6079 
16 15.07958 0.64754 0.6487 
17 15.12238 0.69034 0.6916 
18 15.16474 0.7327 0.7340 
19 15.20188 0.76984 0.7712 
20 15.24196 0.80992 0.8114 
21 15.28286 0.85082 0.8524 
22 15.32499 0.89295 0.8946 
23 15.36353 0.93149 0.9332 
24 15.40079 0.96875 0.9705 






Figure C1 – Plot of volume added vs number of sprays with the equation of best fit line showing 
the volume per spray as the slope 
 
 
 The next step was to determine the mass of drug that reaches the herbal matrix. In the 
process of spraying the drug solution onto the matrix, two variables can lead to the loss of drug. 
One is due to the evaporation itself, and the second is to possible loss due to not actually being 
sprayed onto the herbal mixture. The spray is a mist, so solution could be left behind on weigh 
boat containing the matrix. The loss of drug for each step was evaluated to establish a drug 
concentration to be on the herbal matrix for pyrolysis after the sample preparation step. 
 First was the evaporation alone. This was carried out by removing the variable of the 
spreading mist by spraying the solution directly into a vial. The collected solution was allowed to 
evaporate, reconstituted, spiked with an internal standard and analyzed via GC/MS. The data for 
this step of the study is shown in Table C3. Sample calculations are shown below the table for 
SV1. The mean percent recovery of 69.5 will be used in following steps to calculate the amount 
of drug that should reach the herbal matrix, not barring loss due to mist spreading or being left 
behind on the weigh boat during sample preparation. 
 
y = 0.0403x + 0.0038 



























Number of Sprays 
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Table C3 – Data for determining the loss of drug compound due to evaporation only. 
 
 
𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
𝑀𝑎𝑠𝑠 𝑆𝑡𝑑. 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝑆𝑡𝑑. 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
) 𝑋 (𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑟𝑒𝑎) 
 
𝑀𝑎𝑠𝑠 𝑆𝑉1 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
0.400 𝑚𝑔
34403080
)  𝑋 (53078232) = 6.17 𝑚𝑔 
 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠 = (
𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 𝑉𝑜𝑙𝑢𝑚𝑒
)  𝑋 𝑅𝑒𝑐𝑜𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑖𝑜𝑛 𝑉𝑜𝑙𝑢𝑚𝑒 
 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑆𝑉1 𝑀𝑎𝑠𝑠 = (
6.17 𝑚𝑔
1.5 𝑚𝑙
)  𝑋 4 𝑚𝑙 = 16.5 𝑚𝑔 
 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠
𝐶𝑎𝑓𝑓𝑒𝑖𝑛𝑒 𝑀𝑎𝑠𝑠
)  𝑋 100% 
 
𝑆𝑉1 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (
16.5 𝑚𝑔
20.0 𝑚𝑔
)  𝑋 100% = 82.3% 
 
 Next step was to determine the average amount of drug lost during the sample 
preparation step of spraying the herbal matrix. This could be done in two ways: 1) spray smaller 




















SV1 20.0 4 16.5 82.3 1.5 6.17 530783232 0.400 34403080
SV2 20.0 4 12.8 64.2 1.5 4.81 580927552 0.400 48270736
SV3 20.1 4 12.1 60.2 1.5 4.54 517711232 0.400 45623784
SV4 19.9 4 12.2 61.4 1.5 4.58 452271360 0.400 39483664
SV5 19.9 4 12.5 63.1 1.5 4.71 423705344 0.400 36016228
SV6 19.9 4 13.4 67.5 1.5 5.04 432123520 0.400 34295264
SV7 19.9 4 14.5 73.0 1.5 5.45 475603680 0.400 34917392
SV8 20.1 4 13.5 67.4 1.5 5.08 414302976 0.400 32622774
SV9 20.1 4 15.0 74.5 1.5 5.62 434313696 0.400 30929504
SV10 20.1 4 14.5 72.1 1.5 5.43 428123840 0.400 31511178
SV11 20.0 4 15.8 78.9 1.5 5.91 408213984 0.400 27609438
Mean = 13.9 69.5 Mean = 5.21
Std. Dev. = 1.5 7.2 Std. Dev. = 0.55
Range = 12.4 - 15.4 62.3 - 76.7 Range = 4.66 - 5.76
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between each 2) spray the full volume at once and allow for one evaporation step. After the drug 
was displaced onto the herbal matrix and dried, it was soaked in fresh solvent, spiked with 
internal standard and analyzed via GC/MS. For the calculations, the percent recovery was based 
off of the possible 100% being 69.5% of the total mass due to the evaporation loss from the 
previous step. The data for both applications are shown below in Table C4 and Table C5, and a 
sample calculation of P-SP1 and P-SA1 are shown below. It was observed that the technique of 
spraying the entire drug solution volume onto the herbal matrix at once left a higher amount of 
drug on the matrix at a mean of 75.7%. 
 
Table C4 – Data for the determination of loss due to the spraying of drug solution onto the herbal 
matrix by periodic sprays 
 
 
𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
𝑀𝑎𝑠𝑠 𝑆𝑡𝑑. 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝑆𝑡𝑑. 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
) 𝑋 (𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑟𝑒𝑎) 
 
𝑀𝑎𝑠𝑠 𝑃 − 𝑆𝑃1 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
0.400 𝑚𝑔
29477514
)  𝑋 (160872448) = 2.18 𝑚𝑔 
 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠 = (
𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 𝑉𝑜𝑙𝑢𝑚𝑒























P-SP1 20.0 13.9 6 8.73 62.8 1.5 2.18 160872448 0.400 29477514
P-SP2 19.9 13.8 6 6.97 50.4 1.5 1.74 146505280 0.400 33609992
P-SP3 19.9 13.8 6 6.54 47.3 1.5 1.63 130672840 0.400 31980474
P-SP4 20.0 13.9 6 7.16 51.5 1.5 1.79 132992016 0.400 29715754
P-SP5 20.0 13.9 6 7.80 56.1 1.5 1.95 137002128 0.400 28112380
P-SP6 20.1 14.0 6 8.09 57.9 1.5 2.02 139769264 0.400 27630382
P-SP7 19.9 13.8 6 7.17 51.8 1.5 1.79 130919344 0.400 29215846
P-SP8 20.0 13.9 6 8.07 58.1 1.5 2.02 137043904 0.400 27173758
P-SP9 20.1 14.0 6 8.30 59.4 1.5 2.07 131053472 0.400 25266474
P-SP10 19.9 13.8 6 7.79 56.3 1.5 1.95 132081552 0.400 27121258
Mean = 7.66 55.2 Mean = 1.92
Std. Dev. = 0.68 4.8 Std. Dev. = 0.17
Range = 6.98 - 8.34 47.3 - 62.8 Range = 1.75 - 2.09
Delivered Mass = Caffeine Mass x 69.5%
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𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑃 − 𝑆𝑃1 𝑀𝑎𝑠𝑠 = (
2.18 𝑚𝑔
1.5 𝑚𝑙
)  𝑋 6 𝑚𝑙 = 8.73 𝑚𝑔 
 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠
𝐷𝑒𝑙𝑖𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠
)  𝑋 100% 
 
𝑃 − 𝑆𝑃1 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (
8.73 𝑚𝑔
13.9 𝑚𝑔
)  𝑋 100% = 62.8% 
 
Table C5 – Data for the determination of loss due to the spraying of drug solution onto the herbal 
matrix all at once 
 
 
𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
𝑀𝑎𝑠𝑠 𝑆𝑡𝑑. 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝑆𝑡𝑑. 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
) 𝑋 (𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑟𝑒𝑎) 
 
𝑀𝑎𝑠𝑠 𝑃 − 𝑆𝐴1 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
0.400 𝑚𝑔
29001432
)  𝑋 (177612592) = 2.45 𝑚𝑔 
 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠 = (
𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 𝑉𝑜𝑙𝑢𝑚𝑒
)  𝑋 𝑅𝑒𝑐𝑜𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑖𝑜𝑛 𝑉𝑜𝑙𝑢𝑚𝑒 
 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑃 − 𝑆𝐴1 𝑀𝑎𝑠𝑠 = (
2.45 𝑚𝑔
1.5 𝑚𝑙























P-SA1 20.1 14.0 6 9.80 70.1 1.5 2.45 177612592 0.400 29001432
P-SA2 20.0 13.9 6 10.16 73.1 1.5 2.54 176853472 0.400 27857740
P-SA3 20.1 14.0 6 10.01 71.6 1.5 2.50 180016800 0.400 28779008
P-SA4 20.0 13.9 6 10.17 73.2 1.5 2.54 189699520 0.400 29833854
P-SA5 20.0 13.9 6 8.68 62.4 1.5 2.17 181174656 0.400 33405652
P-SA6 20.1 14.0 6 9.91 70.9 1.5 2.48 175969472 0.400 28413448
P-SA7 20.1 14.0 6 13.81 98.9 1.5 3.45 192910896 0.400 22345990
P-SA8 19.9 13.8 6 11.45 82.8 1.5 2.86 171856880 0.400 24013084
P-SA9 20.1 14.0 6 11.36 81.3 1.5 2.84 170186608 0.400 23964374
P-SA10 20.0 13.9 6 10.12 72.8 1.5 2.53 172357584 0.400 27248658
Mean = 10.5 75.7 Mean = 2.64
Std. Dev. = 1.4 9.9 Std. Dev. = 0.35
Range = 9.1 - 11.9 62.4 - 98.9 Range = 2.29 - 2.99
Delivered Mass = Caffeine Mass x 69.5%
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𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠
𝐷𝑒𝑙𝑖𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠
)  𝑋 100% 
 
𝑃 − 𝑆𝐴1 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (
9.80 𝑚𝑔
14.0 𝑚𝑔
)  𝑋 100% = 70.1% 
 
Lastly, the prepared samples were pyrolyzed to determine the recovery of the burning 
methodology. The calculations were based on the assumptions of the previous two steps; 69.5% 
retention from evaporation and 75.7% of that retention onto the herbal matrix. Samples were 
prepped using the full volume at once technique, and the recovery was evaluated. After a burning 
trial, each collected sample (quartz, tube and flask) was quantified and added together for a total 
collection of drug. The data is presented within Table C6, and a sample calculation is below. 
 
Table C6 – Data for the determination of recovery of overall sample preparation, pyrolysis and 
sample collection process 
 
 
𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
𝑀𝑎𝑠𝑠 𝑆𝑡𝑑. 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝑆𝑡𝑑. 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
























QW1 1 0.00308 0.0293 0.3 0.000925 19049 0.100 2059023
T1 3 1.15 10.9 1.5 0.575961 2414587 0.400 1676910
F1 3 1.53 14.5 1.5 0.763497 3111577 0.400 1630171
Total = 2.68 25.5
QW2 1 0.0217 0.205 0.3 0.00651 159126 0.100 2444907
T2 3 1.80 17.0 1.5 0.90068 4212331 0.400 1870735
F2 3 2.67 25.3 1.5 1.33561 6200113 0.400 1856858
Total = 4.49 42.5
QW3 1 0.226 2.16 0.3 0.0678 1614094 0.100 2381402
T3 3 1.90 18.1 1.5 0.9495 5359954 0.400 2258061
F3 3 4.40 42.0 1.5 2.2003 13377304 0.400 2431886
Total = 6.53 62.3
QW4 1 0.140 1.32 0.3 0.0419 1097624 0.100 2620995
T4 3 1.34 12.7 1.5 0.6719 3866208 0.400 2301586
F4 3 3.21 30.4 1.5 1.6070 9269358 0.400 2307316
Total = 4.70 44.4
QW5 1 0.291 2.8 0.3 0.0872 2119155 0.100 2429536
T5 3 1.48 14.1 1.5 0.7392 4573155 0.400 2474586
F5 3 4.65 44.4 1.5 2.3229 15288100 0.400 2632636
Total = 6.41 61.3
Average = 4.96 47.20








𝑀𝑎𝑠𝑠 𝑄𝑊3 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
0.100 𝑚𝑔
2381402
)  𝑋 (159126) = 0.0678 𝑚𝑔 
 
𝑀𝑎𝑠𝑠 𝑇3 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
0.400 𝑚𝑔
2258061
)  𝑋 (5359954) = 0.950 𝑚𝑔 
 
𝑀𝑎𝑠𝑠 𝐹3 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 = (
0.400 𝑚𝑔
2431886
)  𝑋 (13377304) = 2.20 𝑚𝑔 
 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠 = (
𝑀𝑎𝑠𝑠 𝑆𝑎𝑚𝑝𝑙𝑒 𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑
𝐴𝑛𝑎𝑙𝑦𝑧𝑒𝑑 𝑉𝑜𝑙𝑢𝑚𝑒
)  𝑋 𝑅𝑒𝑐𝑜𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑖𝑜𝑛 𝑉𝑜𝑙𝑢𝑚𝑒 
 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑄𝑊3 𝑀𝑎𝑠𝑠 = (
0.0678 𝑚𝑔
0.3 𝑚𝑙
)  𝑋 1 𝑚𝑙 = 0.226 𝑚𝑔 
 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑇3 𝑀𝑎𝑠𝑠 = (
0.950 𝑚𝑔
1.5 𝑚𝑙
)  𝑋 1 𝑚𝑙 = 1.90 𝑚𝑔 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝐹3 𝑀𝑎𝑠𝑠 = (
2.20 𝑚𝑔
1.5 𝑚𝑙
)  𝑋 1 𝑚𝑙 = 4.40 𝑚𝑔 
 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (
𝑇𝑜𝑡𝑎𝑙 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠
𝐷𝑒𝑙𝑖𝑣𝑒𝑟𝑒𝑑 𝑀𝑎𝑠𝑠
)  𝑋 100% 
 
𝑆𝑎𝑚𝑝𝑙𝑒 1 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = (
6.53 𝑚𝑔
10.47 𝑚𝑔











Proposed Mechanisms of the three major breakdown trends observed: 
 
 The chemistry that takes place within the pyrolytic environment is difficult to fully 
understand. It has long been thought that at extreme temperatures the reactions proceed through 
radical reactions, especially the ring expansion process
1-3
. However, this has not been proven 
through the use of labelled carbon or deuterium studies. For this to occur, the compounds 
involved in the reaction would be forced to initiate the production of a free radical instead of 
more energy favorable electron pushing chemistry while holding true to neutral compounds
4
. 
The common radical hypothesized to be produced is a hydrogen radical, which can take 
approximately 52 kcal/mol to produce 
5
, where hydride shifts are typically closer to 10 kcal/mol 
depending on the state of the carbocation
6
.The mechanism of pyrolytic breakdown on illicit 
drugs is an area largely lacking in experimental data and research. For the current research, the 
proposed mechanisms take the approach of simple electron pushing and hydride shifts as an 
explanation for the three observed trends. This is based on this type of chemical reactions being 
more energy favorable in lieu of producing free radicals. It is not to say that free radicals could 
not be produced and additional mechanism are possible, especially in the extremely high 
temperatures, however, it is hypothesized that these such processes would occur before such 




Figure C2 – Proposed mechanism of a pyrolytic cleavage at the nitrogen within the indole ring 

























Parent Synthetic Cannabinoid to its Proposed Pyrolytic Products Breakdowns: 
 
















































































Shared Proposed Pyrolytic Products from Parent Synthetic Cannabinoid Breakdowns: 
 
 
Figure C19 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C20 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C21 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C22 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C23 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C24 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C25 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C26 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C27 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C28 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C29 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C30 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C31 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C32 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C33 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C34 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C35 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C36 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C37 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 






Figure C38 – Breakdown of parent synthetic cannabinoids that produced the proposed thermal 
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Supplementary Material for Chapter 4: Simultaneous LC/MS/MS Monitoring of Synthetic 
Cannabinoids and Thermal Degradation Products in Postmortem Blood Samples 
 
Table D1 – Compound dependent parameters for the synthetic cannabinoids and observed 
pyrolytic products. * - predicted transition ions and parameters kept the same as cinnoline as the 
compounds differ by a single methyl group and a reference standard was unavailable 
Compound  MRM 
Transition (m/z) 
Compound Dependent Parameters (V) 
Synthetic Cannabinoids DP EP CEP CE CXP 
5F-ADB 
378.2/233.1 77 6 37 30 4 
378.1/213.2 74 9 27 42 3 
  
5F-AMB 
364.3/233.1 85 5 33 30 4 
364.3/213.2 85 5 24 36 4 
  
5F-PB-22 
377.4/232.3 60 5 45 31 6 
377.4/144.2 65 5 20 60 3 
  
AB-CHMINACA 
357.5/241.2 80 10 37 40 4 
357.5/144.9 90 10 15 55 3 
  
AB-FUBINACA 
369.4/253.2 65 6 35 30 4 
369.4/109.2 65 8 23 70 4 
  
AB-PINACA 
331.5/215.3 75 5 36 32 8 
331.5/145.3 75 5 12 50 3 
  
ADB-FUBINACA 
383.5/252.9 90 5 33 32 9 
383.5/108.8 95 4 24 60 3 
  
FUB-AKB-48 
404.5/135.1 100 10 15 27 3 
404.5/107.1 95 10 20 65 3 
  
MAB-CHMINACA 
371.3/241.3 95 5 14 37 4 
371.3/145.1 95 5 20 55 5 
  
MMB-FUBINACA 
384.4/253.1 85 6 36 31 9 
384.4/225.1 85 6 26 43 4 
143 
 
Pyrolytic Products   
1-Methylindazole 
133.2/117.9 58 9 11 32 3 
133.2/91.2 60 7 31 42 3 
  
4-Hydroxycinnoline 
147.3/92.1 67 11 12 29 2 




147.3/117.8 50 8 13 38 3 
147.3/91.8 55 8 11 26 3 
  
1-Pentylindazole 
189.2/133.5 40 4 20 22 4 
189.2/119.2 40 4 15 35 3 
  
Indazole 
119.3/92.0 52 11 11 30 3 
119.3/65.8 53 11 11 45 2 
  
4-Methylcinnoline* 
144.2/102.2 80 10 13 34 4 
144.2/77.0 80 10 12 37 3 
  
Cinnoline 
130.7/102.2 80 10 13 34 4 








LOD (ng/ml) LOQ (ng/ml) 
5F-ADB 1.0 - 1,000.0 0.1  ≥ x ≤ 1.0 10.0 
5F-AMB 1.0 - 1,000.0 1.0 ≥ x ≤ 10.0 10.0 
5F-PB-22 0.1 - 1,000.0 0.01 ≥ x ≤ 0.1 1.0 
AB-CHMINACA 1.0 - 1,000.0 0.1  ≥ x ≤ 1.0 10.0 
AB-FUBINACA 1.0 - 1,000.0 0.1  ≥ x ≤ 1.0 10.0 
AB-PINACA 1.0 - 1,000.0 0.1  ≥ x ≤ 1.0 10.0 
ADB-FUBINACA 1.0 - 1,000.0 0.1  ≥ x ≤ 1.0 10.0 
FUB-AKB-48 1.0 - 1,000.0 1.0 ≥ x ≤ 10.0 10.0 
MAB-CHMINACA 1.0 - 1,000.0 0.1  ≥ x ≤ 1.0 10.0 





Table D3 – Precision and accuracy data for both within-day and between-day evaluations 
Parent Compound 
Precision (%CV) Accuracy (avg. % difference, ±%CV of x̅) 
Within-day; n=5 Between-day; n=10 Within-day; n=5 Between-day; n=10 
Low Mid High Low Mid High Low Mid High Low Mid High 
5F-ADB 1.7 7.0 20.3 1.6 7.6 18.2 11.9 11.4 10.1 17.4 11.4 0.3 
5F-AMB 0.9 6.4 6.7 1.2 6.8 18.8 15.9 10.9 0.0 4.4 7.4 2.5 
5F-PB-22 8.8 9.7 17.3 8.9 8.6 12.5 3.8 1.6 6.2 2.7 0.6 0.0 
AB-CHMINACA 5.6 8.4 10.3 7.9 9.3 9.2 1.4 1.9 4.7 12.0 0.5 0.1 
AB-FUBINACA 6.5 8.5 19.4 6.7 9.0 15.3 0.5 2.4 4.5 9.2 0.9 0.4 
AB-PINACA 13.4 19.5 20.7 14.2 11.9 20.5 15.7 13.5 14.8 0.5 0.0 0.0 
ADB-FUBINACA 0.9 3.1 10.3 0.8 3.6 18.8 14.4 7.4 19.0 4.2 4.8 0.0 
FUB-AKB-48 8.4 16.5 17.1 8.3 16.3 20.9 17.0 4.6 4.1 4.2 3.4 1.5 
MAB-CHMINACA 7.3 10.9 13.3 14.6 11.0 18.3 1.7 18.2 6.2 17.8 17.5 1.5 
MMB-FUBINACA 0.5 6.1 9.7 0.9 9.2 18.6 3.1 13.6 5.7 5.6 21.9 0.4 
 
 
Table D4 – Average extraction recoveries and matrix effects; analyzed at n = 3 
Parent Compound 
Matrix Effect Recovery 
50 ng/ml 500 ng/ml 50 ng/ml 500 ng/ml 
5F-ADB 76.9 67.9 97.4 86.4 
5F-AMB 112.3 59.8 70.2 77.6 
5F-PB-22 41.9 98.3 136.2 130.0 
AB-CHMINACA 81.8 155.7 78.8 165.2 
AB-FUBINACA 97.1 79.6 86.5 64.7 
AB-PINACA 85.1 80.5 141.9 73.4 
ADB-FUBINACA 136.1 92.3 129.6 131.8 
FUB-AKB-48 85.4 80.8 76.7 65.5 
MAB-CHMINACA 105.2 113.2 105.7 119.0 







Supporting data that was not included in the manuscript for chapter 4. 
Predicted pyrolytic products of the synthetic cannabinoids present in the obtained case blood 
samples: 
 





























Figure E7 – Possible thermal degradation products for the parent synthetic cannabinoid,  





























Method validation linearity graphs and example chromatographs: 
 





Figure E12 – Linearity plot of concentration (1 – 100 ng/ml) vs intensity for 5F-AMB 
 
 
y = 1.0143x + 8.9418 




















y = 3.2816x - 5.6264 






























Figure E14 – Linearity plot of concentration (1 – 100 ng/ml) vs intensity for AB-CHMINACA 
 
 
y = 10.135x + 19.27 
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Figure E16 – Linearity plot of concentration (1 – 100 ng/ml) vs intensity for AB-PINACA 
 
y = 5.4578x + 0.9797 




















y = 1.1276x + 10.04 
































Figure E18 – Linearity plot of concentration (1 – 100 ng/ml) vs intensity for FUB-AKB-48 
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LC chromatograms of the parent method and examples of a few blood samples: 
 















































Figure E30 – Example LC Chromatogram of a blood sample containing 4-methylcinnoline 
